Pressure BioSciences (PBIO) 10-K 2 Apr 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 23, 2018	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	PRESSURE BIOSCIENCES INC
Entity Central Index Key	830,656
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 6,981,053
Entity Common Stock, Shares Outstanding		1,367,852
Trading Symbol	PBIO
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 81,033	$ 138,363
Accounts receivable, net of $0 reserve at December 31, 2017 and $28,169 at December 31, 2016	206,848	281,320
Inventories, net of $179,600 reserve at December 31, 2017 and $20,000 December 31, 2016	857,662	905,284
Prepaid income taxes	7,482	7,405
Prepaid expenses and other current assets	214,676	258,103
Total current assets	1,367,701	1,590,475
Investment in available-for-sale equity securities	19,825	25,865
Property and equipment, net	22,662	9,413
Intangible assets, net	750,000
TOTAL ASSETS	2,160,188	1,625,753
CURRENT LIABILITIES
Accounts payable	589,263	407,249
Accrued employee compensation	368,700	249,596
Accrued professional fees and other	800,620	610,589
Other current liabilities	1,536,507	346,295
Deferred revenue	263,106	159,654
Revolving note payable, net of unamortized debt discounts of $0 and $637,030, respectively	3,500,000	612,970
Related party convertible debt, net of unamortized debt discounts of $31,372 and $0, respectively	259,762
Convertible debt, net of unamortized discounts of $401,856 and $2,235,839, respectively	8,028,014	4,005,702
Other debt, net of unamortized discounts of $48,194 and $380, respectively	1,379,863	238,157
Warrant derivative liabilities		1,685,108
Conversion option derivative liabilities		951,059
Total current liabilities	16,725,835	9,266,379
LONG TERM LIABILITIES
Related party convertible debt, net of unamortized debt discounts of $0 and $165,611, respectively		125,523
Convertible debt, net of unamortized discounts of $0 and $740,628, respectively		529,742
Deferred revenue	57,149	87,527
TOTAL LIABILITIES	16,782,984	10,009,171
COMMITMENTS AND CONTINGENCIES (Note 7)
STOCKHOLDERS’ DEFICIT
Common stock, $.01 par value; 100,000,000 shares authorized; 1,342,858 and 1,033,328 shares issued and outstanding on December 31, 2017 and 2016, respectively	13,429	10,333
Warrants to acquire common stock	9,878,513	6,325,102
Additional paid-in capital	30,833,549	27,544,265
Accumulated other comprehensive loss
Accumulated deficit	(55,349,299)	(42,264,190)
Total stockholders’ deficit	(14,622,796)	(8,383,418)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	2,160,188	1,625,753
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock, value	3	3
Series G Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock, value	806	866
Series H Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock, value	100	100
Series H2 Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock, value
Series J Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock, value	35	35
Series K Convertible Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Convertible Preferred Stock, value	$ 68	$ 68

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Accounts receivable, reserve	$ 0	$ 28,169
Inventories reserve	179,600	20,000
Revolving note payable, unamortized discount	0	637,030
Convertible debt related party unamortized debt discount current, net	31,372	0
Convertible debt, current unamortized discounts	401,856	2,235,839
Other debt, unamortized discounts net	48,194	380
Convertible debt related party unamortized debt discount net	0	165,611
Convertible debt, non current unamortized discounts	$ 0	$ 740,628
Convertible preferred stock, par value	$ 0.01
Convertible preferred stock, authorized	1,000,000
Convertible preferred stock, shares issued	1,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	1,342,858	1,033,328
Common stock, shares outstanding	1,342,858	1,033,328
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ .01
Convertible preferred stock, authorized	850	850
Convertible preferred stock, shares issued	300	300
Convertible preferred stock, shares outstanding	300	300
Convertible preferred stock, liquidation value	$ 300,000	$ 300,000
Series G Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	240,000	240,000
Convertible preferred stock, shares issued	80,570	86,570
Convertible preferred stock, shares outstanding	80,570	86,570
Series H Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	10,000	10,000
Convertible preferred stock, shares issued	10,000	10,000
Convertible preferred stock, shares outstanding	10,000	10,000
Series H2 Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	21	21
Convertible preferred stock, shares issued	21	21
Convertible preferred stock, shares outstanding	21	21
Series J Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	6,250	6,250
Convertible preferred stock, shares issued	3,458	3,521
Convertible preferred stock, shares outstanding	3,458	3,521
Series K Convertible Preferred Stock [Member]
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, authorized	15,000	15,000
Convertible preferred stock, shares issued	6,880	6,816
Convertible preferred stock, shares outstanding	6,880	6,816

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue:
Products, services, other	$ 2,065,891	$ 1,794,749
Grant revenue	174,607	181,738
Total revenue	2,240,498	1,976,487
Costs and expenses:
Cost of products and services	1,273,354	834,012
Research and development	988,597	1,183,011
Selling and marketing	1,209,334	872,365
General and administrative	3,416,261	2,822,752
Total operating costs and expenses	6,887,546	5,712,140
Operating loss	(4,647,048)	(3,735,653)
Other (expense) income:
Interest expense	(6,055,420)	(4,501,186)
Other expense	(5,674)	(1,112)
Impairment loss on investment	(6,069)	(373,682)
Gain on extinguishment of debt	185,452	5,044
Incentive warrants for warrant exercises	(186,802)
Change in fair value of derivative liabilities		5,904,649
Total other (expense) income	(6,068,513)	1,028,669
Net loss	$ (10,715,561)	$ (2,706,984)
Net loss per share - basic and diluted	$ (9.62)	$ (2.97)
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation	1,114,225	911,312

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Comprehensive Loss
Net loss	$ (10,715,561)	$ (2,706,984)
Other comprehensive loss
Reclassification of unrealized loss to realized loss on marketable securities		105,025
Comprehensive loss	$ (10,715,561)	$ (2,601,959)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Series D Preferred Stock [Member]	Series G Preferred Stock [Member]	Series H Preferred Stock [Member]	Series H(2) Preferred Stock [Member]	Series J Preferred Stock [Member]	Series K Preferred Stock [Member]	Common Stock [Member]	Stock Warrants [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2015	$ 3	$ 866	$ 100		$ 36	$ 114	$ 7,668	$ 5,416,681	$ 26,259,115	$ (105,025)	$ (39,557,206)	$ (7,977,648)
Balance, shares at Dec. 31, 2015	300	86,570	10,000	21	3,546	11,416	766,830
Stock-based compensation									379,964			379,964
Issuance of common stock for services							$ 252		332,444			332,696
Issuance of common stock for services, shares							25,167
Warrant revaluation
Warrant exercise							$ 8	(11,100)	11,092
Warrant exercise, shares							766
Stock exchange with Everest Investments
Stock exchange with Everest Investments, shares
Issuance of warrants for services								84,735				84,735
Conversion of debt and interest for commons stock							$ 140		117,697			117,837
Conversion of debt and interest for commons stock, shares							14,028
Issuance of common stock for dividends paid-in-kind							$ 83		63,772			63,855
Issuance of common stock for dividends paid-in-kind							8,285
Conversion of Series J convertible preferred stock					$ (1)		$ 8		(7)
Conversion of Series J convertible preferred stock, shares					(25)		833
Conversion of Series K convertible preferred stock						$ (46)	$ 1,533		(1,487)
Conversion of Series K convertible preferred stock, shares						(4,600)	153,333
Common stock offering							$ 508	315,301	294,191			610,000
Common stock offering, shares							50,834
Offering costs for issuance of common stock									(79,035)			(79,035)
Stock issued with debt							$ 133		145,798			145,931
Stock issued with debt, shares							13,252
Warrants issued with debt								519,485				519,485
Unrealized loss on investments, net of tax										105,025		105,025
Offering costs for issuance of common stock									(79,035)			(79,035)
Beneficial conversion feature									20,721			20,721
Net loss											(2,706,984)	(2,706,984)
Balance at Dec. 31, 2016	$ 3	$ 866	$ 100		$ 35	$ 68	$ 10,333	6,325,102	27,544,264		(42,264,190)	(8,383,418)
Balance, shares at Dec. 31, 2016	300	86,570	10,000	21	3,521	6,816	1,033,328
Stock-based compensation									406,427			406,427
Issuance of common stock for services							$ 57		46,935			46,992
Issuance of common stock for services, shares						64	5,667
Warrant revaluation
Issuance of warrants for services								15,558				$ 15,558
Conversion of debt and interest for commons stock, shares												61,307
Issuance of common stock for dividends paid-in-kind							$ 612		263,990			$ 264,602
Issuance of common stock for dividends paid-in-kind							61,307
Conversion of Series J convertible preferred stock							$ 21		(21)
Conversion of Series J convertible preferred stock, shares					(63)		2,100
Offering costs for issuance of common stock												1,400,000
Stock issued with debt							$ 645		$ 367,929			368,574
Stock issued with debt, shares							64,400
Early adoption of ASU 2017-11								$ 2,636,236	$ 1,446,011		(2,369,548)	1,712,699
Early adoption of ASU 2017-11, shares
Warrant exercise, net of costs							$ 199		140,015			140,214
Warrant exercise, net of costs, shares							19,889
Conversion of Series G convertible preferred stock		$ (60)					$ 20		40
Conversion of Series G convertible preferred stock, shares		(6,000)					2,000
Incentive warrants								186,802				186,802
Incentive warrants, shares
Stock issued for debt extension							$ 42		19,458			19,500
Stock issued for debt extension, shares							4,167
Common stock for asset purchase							$ 1,500		598,500			600,000
Common stock for asset purchase, shares							150,000
Warrants issued with debt								714,815				714,815
Warrants issued with debt, shares
Net loss											(10,715,561)	(10,715,561)
Balance at Dec. 31, 2017	$ 3	$ 806	$ 100		$ 35	$ 68	$ 13,429	$ 9,878,513	$ 30,833,549		$ (55,349,299)	$ (14,622,796)
Balance, shares at Dec. 31, 2017	300	80,570	10,000	21	3,458	6,880	1,342,858

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,715,561)	$ (2,706,984)
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued for debt extension	19,500
Depreciation and amortization	8,576	17,939
Provision for bad debts		28,169
Inventory reserve	159,600
Accretion of interest and amortization of debt discount	4,128,637	4,003,485
Incentive warrants for warrant exercises	186,802
Penalty interest added to debt principal		41,200
Gain on settlement of debt	(185,452)	(5,044)
Stock-based compensation expense	406,427	379,964
Warrants issued for service	15,558	84,735
Shares issued for service	31,000
Amortization of third party fees paid in common stock and warrants		332,696
Impairment loss on investment	6,069	373,682
Change in fair value of derivative liabilities		(5,904,649)
Changes in operating assets and liabilities:
Accounts receivable	74,472	(196,233)
Inventories	(111,978)	133,087
Prepaid expenses and other assets	59,312	(44,201)
Accounts payable	182,014	(534,140)
Accrued employee compensation	119,104	73,587
Accrued interest	898,212	346,295
Deferred revenue and other accrued expenses	813,159	(229,439)
Net cash used in operating activities	(3,904,549)	(3,805,851)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of intangible assets	(150,000)
Purchases of property plant and equipment	(21,825)	(7,203)
Net cash used in investing activities	(171,825)	(7,203)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from related party debt		116,667
Payment of related party debt		(20,000)
Net proceeds from revolving note payable	2,070,000	1,133,500
Net proceeds from convertible debt	1,755,850	2,105,420
Payments on convertible debt	(925,541)	(107,000)
Net proceeds from non-convertible debt	2,905,752	1,022,784
Payments on non-convertible debt	(1,894,231)	(947,702)
Net proceeds from warrant exercises	140,214
Payments on prepayment penalty	(33,000)
Net proceeds from the issuance of common stock		530,965
Net cash provided by financing activities	4,019,044	3,834,634
NET (DECREASE) INCREASE IN CASH	(57,330)	21,580
CASH AT BEGINNING OF YEAR	138,363	116,783
CASH AT END OF Year	81,033	138,363
SUPPLEMENTAL INFORMATION
Interest paid in cash	533,532	260,979
NON CASH TRANSACTIONS:
Convertible debt exchanged for common stock		117,837
Cashless exercise of warrants		11,100
Discount due to beneficial conversion feature		20,721
Discount due to warrants issued with debt	714,815	519,485
Common stock issued with debt	368,574	104,731
Common stock issued to purchase intangible assets	600,000
Common stock issued to settle non-convertible debt		41,200
Common stock issued in lieu of cash for interest	264,602
Common stock issued for prepaid services	15,992
Conversion of preferred stock and accrued dividends into common stock	61	63,902
Discount from derivative liability		1,304,049
Discount from one-time interest	225,000	170,000
Reclassification of derivative liabilities to equity and cumulative effect of adoption of ASU 2017-11	1,712,699
Reversal of accumulated other comprehensive income to impairment loss on investment		$ 105,025

Business Overview

Business Overview	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview	(1) Business Overview Pressure Biosciences, Inc. (“we”, “our”, “the Company”) is focused on solving the challenging problems inherent in biological sample preparation, a crucial laboratory step performed by scientists worldwide working in biological life sciences research. Sample preparation is a term that refers to a wide range of activities that precede most forms of scientific analysis. Sample preparation is often complex, time-consuming, and in our belief, one of the most error-prone steps of scientific research. It is a widely-used laboratory undertaking, the requirements of which drive what we believe is a large and growing worldwide market. We have developed and patented a novel, enabling technology platform that can control the sample preparation process. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (35,000 psi or greater) to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. Our pressure cycling technology uses internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels - at controlled temperatures and specific time intervals - to rapidly and repeatedly control the interactions of bio-molecules, such as DNA, RNA, proteins, lipids, and small molecules. Our laboratory instrument, the Barocycler®®, and our internally developed consumables product line, including PULSE® (Pressure Used to Lyse Samples for Extraction) Tubes, other processing tubes, and application specific kits (which include consumable products and reagents) together make up our PCT Sample Preparation System, or PCT SPS. In 2015, together with an investment bank, we formed a subsidiary called Pressure BioSciences Europe (“PBI Europe”) in Poland. We have 49% ownership interest with the investment bank retaining 51%. As of now, PBI Europe does not have any operating activities and we cannot reasonably predict when operations will commence. Therefore, we do not have control of the subsidiary and did not consolidate in our financial statements. PBI Europe did not have any operations in 2017 or in 2016. Reverse Stock Split On June 5, 2017, the Company effected a 1-for-30 reverse stock split of its issued and outstanding shares of common stock All common shares, stock options, and per share information presented in the financial statements have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented. The ratio by which shares of preferred stock are convertible into shares of common stock were adjusted to reflect the effects of the reverse stock split.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	(2) Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of December 31, 2017, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising cash through debt and equity offerings in the past and as described in Notes 8 and 9, completed debt financing subsequent to December 31, 2017. We have financing efforts in place to continue to raise cash through debt and equity offerings. Management has developed a plan to continue operations. This plan includes obtaining equity or debt financing. During the year ended December 31, 2017 we received approximately $6.7 million net proceeds, in additional convertible and non-convertible debt. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful. Management’s plans to alleviate these conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern include pursuing one or more of the following options to raise additional funding, none of which can be guaranteed or are entirely within the Company’s control: ● Raise funding through the possible additional sales of the Company’s common stock, including public or private equity financings. ● Raise additional loan funding. ● Continue to seek a partner to advance PCT technology. ● Earn payments pursuant to potential collaboration and license agreements for BaroFold patents. There can be no assurance, however, that the Company will receive cash proceeds from any of these potential resources or, to the extent cash proceeds are received, those proceeds would be sufficient to support the Company’s operations for at least the next twelve months from the date of filing this Annual Report on Form 10-K. In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Generally, under the new accounting standard, management’s plans must be approved before the date the financial statements are issued to be considered probable of being effectively implemented. Under the new accounting standard, the future receipt of potential funding from the Company’s collaborators and other resources is not considered probable at this time because none of the Company’s current plans have been finalized at the time of filing this Annual Report on Form 10-K. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The Company believes that its approximate $80,033 in cash and cash equivalents at December 31, 2017 would allow it to fund its planned operations into the first quarter of 2018. This estimate assumes no additional funding from new partnership agreements, no additional equity financings, no debt financings, and no accelerated repayment of its term loans. Accordingly, the timing and nature of activities contemplated for the remainder of 2017 and thereafter will be conducted subject to the availability of sufficient financial resources. If the Company is unable to raise capital when needed or on attractive terms, or if it is unable to procure partnership arrangements to advance its programs, the Company would be forced to delay, reduce or eliminate its research and development programs and any future commercialization efforts. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(3) Summary of Significant Accounting Policies i. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation. ii. Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify impairment of assets, deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded, beneficial conversion features and derivative liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used. iii. Revenue Recognition Revenue is recognized when realized or when realizable and earned when all the following criteria have been met: persuasive evidence of an arrangement exists; goods were shipped, delivery of service has occurred and risk of loss has passed to the customer; the seller’s price to the buyer is fixed or determinable; and collectability is reasonably assured. Our current instruments, the Barocycler NEP3229 and NEP2320EXT, require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Product revenue related to current Barocycler instrumentation is recognized upon shipment of the unit, and in the case where the customer requests installation and training, the completion of the installation and introductory training process of the instrumentation at the customer location, for domestic installations. Product revenue related to sales of PCT instrumentation to our foreign distributors is recognized upon shipment through a common carrier. We provide for the expected costs of warranty upon the recognition of revenue for the sales of our instrumentation. Our sales arrangements do not provide our customers with a right of return. Product revenue related to the HUB440 and our consumable products such as PULSE Tubes, MicroTubes, and application specific kits is recorded upon shipment through a common carrier. Shipping costs are included in sales and marketing expense. Any shipping costs billed to customers are recognized as revenue. The Company applies ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. The Company currently records revenue for its non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for our lease agreements under the operating method. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when qualifying expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and the Company’s service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying deliverables. Revenue from service contracts is recorded ratably over the length of the contract. Our transactions sometimes involve multiple elements (i.e., products and services). Revenue under multiple element arrangements is recognized in accordance with FASB ASC 605-25 Multiple-Element Arrangements (“ASC 605”) iv. Cash and Cash Equivalents Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents. Restricted cash is included in cash equivalents. v. Research and Development Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life. vi. Inventories Inventories are valued at the lower of cost (average cost) or net realizable value. The cost of Barocyclers consists of the cost charged by the contract manufacturer. The current year allowance was increased by a $159,600 inventory allowance for the older generation of Barocycler instruments held in stock, the NEP3229. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: 2017 2016 Raw materials $ 288,295 $ 326,228 Finished goods 748,967 599,056 Inventory reserve (179,600 ) (20,000 ) Total $ 857,662 $ 905,284 vii. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets. viii. Intangible Assets We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over nine years. We perform an annual review of our intangible assets for impairment. We capitalize any costs to renew or extend the term of our intangible assets. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. As of December 31, 2017 and 2016, the outstanding balance for intangible assets was $750,000 and $0, respectively. ix. Long-Lived Assets The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment x. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2017, we determined that no allowance against accounts receivable was necessary and wrote off the prior year allowance of $28,169 as unrecoverable. The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: 2017 2016 Top Five Customers 37 % 29 % Federal Agencies 14 % 3 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2017 2016 Top Five Customers 85 % 82 % Federal Agencies 1 % 1 % Investment in Available-For-Sale Equity Securities As of December 31, 2017, we held 100,250 shares of common stock of Everest, a Polish publicly traded company listed on the Warsaw Stock Exchange. We exchanged 33,334 shares of our common stock for the 100,250 shares from Everest. We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities” xi. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31: 2017 2016 Numerator: Net loss $ (10,715,561 ) $ (2,706,984 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 1,114,225 911,312 Loss per common share - basic and diluted $ (9.62 ) $ (2.97 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: 2017 2016 Stock options 247,692 175,642 Convertible debt 947,203 891,132 Common stock warrants 899,542 881,990 Convertible preferred stock: Series D Convertible Preferred 25,000 25,000 Series G Convertible Preferred 26,857 28,857 Series H Convertible Preferred 33,334 33,334 Series H2 Convertible Preferred 70,000 70,000 Series J Convertible Preferred 115,267 117,367 Series K Convertible Preferred 229,334 227,200 2,594,229 2,450,522 xii. Accounting for Income Taxes We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income. Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2017 and 2016, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2017 and 2016. xiii. Accounting for Stock-Based Compensation We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Employee awards are accounted for under ASC 718 where the awards are valued at grant date. Awards given to nonemployees are accounted for under ASC 505 where the awards are valued at earlier of commitment date or completion of services. Determining Fair Value of Stock Option Grants Valuation and Amortization Method Expected Term Compensation-Stock Compensation Expected Volatility Risk-Free Interest Rate Forfeitures Compensation-Stock Compensation The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2017: Assumptions Non-Employee Board Members CEO, other Officers and Employees Expected life 6.0 (yrs ) 6.0 (yrs ) Expected volatility 92.85%-104.83 % 105.71 % Risk-free interest rate 1.01%-1.53 % 1.63 % Forfeiture rate 5.00 % 5.00 % Expected dividend yield 0.0 % 0.0 % We recognized stock-based compensation expense of $406,427 and $379,964 for the years ended December 31, 2017 and 2016, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying consolidated statements of operations for the years ended December 31: 2017 2016 Research and development $ 92,055 $ 65,500 Selling and marketing 54,404 42,315 General and administrative 259,968 272,149 Total stock-based compensation expense $ 406,427 $ 379,964 During the years ended December 31, 2017 and 2016, the total fair value of stock options awarded was $487,964 and $0, respectively. As of December 31, 2017, total unrecognized compensation cost related to the unvested stock-based awards was $392,590, which is expected to be recognized over weighted average period of 1.66 years. xiv. Advertising Advertising costs are expensed as incurred. We incurred $5,899 in 2017 and $19,125 in 2016 for advertising. xv. Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Short-term and long-term liabilities are primarily related to liabilities transferred under contractual arrangements with carrying values that approximate fair value. xvi. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ASC 820 The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are currently classified within Level 1 and that its financial liabilities are currently all classified within Level 3 in the fair value hierarchy. The Company changed its method of accounting for the Debentures and Warrants through the early adoption of ASU 2017-11 during the year ended December 31, 2017 on a modified retrospective basis. Accordingly, the Company reclassified the warrant derivative and conversion option derivative liabilities to additional paid in capital on its January 1, 2017 consolidated balance sheets totaling approximately $2.6 million, reduced debt discount by approximately $0.9 million and recorded the cumulative effect of the adoption to the beginning balance of accumulated deficit of approximately $2.5 million. Adoption of ASU 2017-11 The Company changed its method of accounting for the Debentures, Debenture Warrants and Series D Warrants through the early adoption of ASU 2017-11 during the year ended December 31, 2017 on a modified retrospective basis. Accordingly, the Company reclassified the warrant derivative and conversion option derivative liabilities to additional paid in capital on its January 1, 2017 consolidated balance sheets totaling approximately $2.6 million, reduced debt discount by approximately $0.9 million and recorded the cumulative effect of the adoption to the beginning balance of accumulated deficit of approximately $2.4 million. This resulted to an increase in stock warrants by $2.6 million and additional paid-in capital by $1.4 million. The following table provides a reconciliation of the warrant derivative liability, convertible debt, conversion option derivative liability, stock warrant, additional paid-in capital and accumulated deficit on the consolidated balance sheet as of December 31, 2016: Convertible debt, current portion Convertible debt, long term portion Warrant Derivative Liability Conversion Option Liability Warrants to acquire common stock Additional Paid-in Capital Accumulated deficit Balance, January 1, 2017 (Prior to adoption of ASU 2017-11) $ 4,005,702 $ 529,742 $ 1,685,108 $ 951,059 $ 6,325,102 $ 27,544,265 $ (42,264,190 ) Reclassified derivative liabilities and cumulative effect of adoption 769,316 154,152 $ (1,685,108 ) (951,059 ) 2,636,236 1,446,011 (2,369,548 ) Balance, January 1, 2017 (After adoption of ASU 2017-11) $ 4,775,018 $ 683,894 $ - $ - $ 8,961,338 $ 28,990,276 $ (44,633,738 ) The following tables set forth the Company’s financial assets and financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2017 and December 31, 2016. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. Fair value measurements at December 31, 2017 using: December 31, 2017 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 19,825 19,825 - - Total Financial Assets $ 19,825 $ 19,825 $ - $ - Fair value measurements at December 31, 2016 using: December 31, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 25,865 25,865 - - Total Financial Assets $ 25,865 $ 25,865 $ - $ - December 31, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 23,313 - - $ 23,313 Warrants Issued with Convertible Debt 1,661,795 - - 1,661,795 Conversion Option Derivative Liabilities 951,059 - - 951,059 Total Derivatives $ 2,636,167 $ - $ - $ 2,636,167 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: January 1, 2016 Issuance fair value Change in fair value December 31, 2016 Series D Preferred Stock Purchase Warrants $ 173,526 $ - $ (150,213 ) $ 23,313 Warrants Issued with Convertible Debt 3,122,450 1,094,432 (2,555,087 ) 1,661,795 Conversion Option Derivative Liabilities 3,940,791 1,547,127 (4,536,859 ) 951,059 Total Derivatives $ 7,236,767 $ 2,641,559 $ (7,242,159 ) $ 2,636,167 The issuance fair values for 2016 include the “day 1” derivative losses on the conversion option derivative liabilities of $1,337,510, which are included in “change in fair value of derivative liabilities” in the consolidated statements of operations. There were no derivative liabilities as of December 31, 2017. The fair value of the derivative liabilities was determined using a binomial pricing model. The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2016 Expected life (in months) 60.0 5.0 Expected volatility 104.5 % 83.5 % Risk-free interest rate 0.875 % 0.62 % Exercise price $ 24.30 $ 7.50 Fair value per warrant $ 16.20 $ 0.60 The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt in 2016 reflected on a per share common stock equivalent basis. Assumptions At Issuance Fair value Warrants revalued at December 31, 2016 Expected life (in months) 60.0 43.0-51.0 Expected volatility 118.3-120.1 % 110.0-116.0 % Risk-free interest rate 1.48-1.69 % 1.93 % Exercise price $ 12.00 $ 12.00 Fair value per warrant $ 5.70-$6.30 $ 3.60-4.20 The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value At Settlement fair value Conversion options revalued at December 31, 2016 Expected life (in months) 6.0-24.0 0-18.0 6.0-15.0 Expected volatility 104.2-153.8 % 86.9%-142.2 % 84.4-94.8 % Risk-free interest rate 0.05-0.99 % 0.01-0.72 % 0.62-0.85 % Exercise price $ 3.00-$10.50 $ 3.00-$7.50 $ 8.40 Fair value per conversion option $ 2.70-$8.40 $ 2.10-$7.80 $ 0.90-$1.80 xvii. Reclassifications Certain prior year amounts have been reclassified to conform to our current year presentation. xviii. Recently Issued Accounting Standards In November 2016, the Financial Accounting Standards Board (the FASB) issued Accounting Standards Update (ASU) No. 2016-18 (ASU 2016-18). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017. As early adoption of this amendment is permitted, the Company has adopted the update retrospectively to each period presented. The adoption of this guidance did not have a material impact on the company’s consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-09, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 became effective for the Company on January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s consolidated Financial Statements. In February 2016, the FASB issued ASU 2016-02, which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated Financial Statements. In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) which amended the existing accounting standards for revenue recognition. ASU 2014-09 establishes principles for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the expected consideration received in exchange for those goods or services. In July 2015, the FASB deferred the effective date for annual reporting periods beginning after December 15, 2017 (including interim reporting periods within those periods). The amendments may be applied retrospectively to each prior period (full retrospective) or retrospectively with the cumulative effect recognized as of the date of initial application (modified retrospective). The Company will adopt ASU 2014-09 in the first quarter of 2018 and apply the modified retrospective approach. The Company’s primary source of revenues is from instrument sales which are considered distinct performance obligations and are recognized upon shipment, the Company does not expect the impact on its consolidated financial statements to be material.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	(4) Property and Equipment, net Property and equipment as of December 31, 2017 and 2016 consisted of the following components: December 31, 2017 2016 Laboratory and manufacturing equipment $ 240,670 $ 226,326 Office equipment 173,312 165,832 Leasehold improvements 8,117 8,117 PCT collaboration, demonstration and leased systems 461,858 461,858 Total property and equipment 883,957 862,133 Less accumulated depreciation (861,295 ) (852,720 ) Net book value $ 22,662 $ 9,413 Depreciation expense for the years ended December 31, 2017 and 2016 was $8,576 and $17,939, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	(5) Intangible Assets Intangible assets as of December 31, 2017 reflect the purchase price attributable to patents received in connection with the acquisition of assets of BaroFold Corp. Acquired BaroFold patents are being amortized to expense on a straight line basis at the rate of $80,000 per year over their estimated remaining useful lives of approximately 9 years. The estimated aggregate amortization expense for each of the five succeeding fiscal years is $80,000 annually. We performed a review of our intangible assets for impairment. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. An impairment analysis of intangible assets was performed as of December 31, 2017. We have concluded that there is no impairment of intangible assets. Intangible assets at December 31, 2017 and 2016 consisted of the following: December 31, 2017 2016 BaroFold Patents $ 750,000 $ - Less accumulated amortization - - Net book value $ 750,000 $ - Amortization expense for each of the years ended December 31, 2017 and 2016 was $0.

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2017
Retirement Benefits [Abstract]
Retirement Plan	(6) Retirement Plan We provide all of our employees with the opportunity to participate in our retirement savings plan. Our retirement savings plan has been qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the plan through payroll deductions within statutory limitations and subject to any limitations included in the plan. During 2017 and 2016 we contributed $13,587 and $22,627, respectively, in the form of discretionary Company-matching contributions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	(7) Income Taxes Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2017 and 2016, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2017 and 2016. Our tax returns for fiscal years 2014, 2015 and 2016 are open to examination. We did not record an income tax benefit or provision for the years ended December 31, 2017 and 2016. Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2017 and 2016 are as follows: 2017 2016 Long term deferred taxes: Inventories $ 49,067 $ 7,856 Accounts receivable allowance - 17,253 Other accruals 75,992 33,399 Accelerated tax depreciation 6,945 14,582 Non-cash, stock-based compensation, nonqualified 606,020 711,676 Impairment loss on investment 103,748 146,782 Goodwill and intangibles - - Operating loss carry forwards and tax credits 12,196,765 13,561,012 Less: valuation allowance (13,038,537 ) (14,492,560 ) Total net deferred tax assets $ - $ - A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. Accordingly, a valuation allowance was established in 2017 and 2016 for the full amount of our deferred tax assets due to the uncertainty of realization. We believe based on our projection of future taxable operating income for the foreseeable future, it is more likely than not that we will not be able to realize the benefit of the deferred tax asset at December 31, 2017. On December 22, 2017, the U.S. Tax Cuts and Jobs Act (the "Tax Reform Act") was signed into law by President Trump. The Tax Reform Act significantly revised the U.S. corporate income tax regime by, among other things, lowering the U.S. corporate tax rate from 35% to 21% effective January 1, 2018. Under ASC 740, the tax effects of changes in tax laws must be recognized in the period in which the law was enacted. ASC 740 also requires deferred tax assets and liabilities to be measured at the enacted tax rate expected to apply when temporary differences are to be realized or settled. The Company re-measured its deferred tax assets and liabilities at the 21% federal corporate tax rate. The remeasurement resulted in no change in the Company’s recorded tax provision, as the remeasurement of the company's deferred tax assets and liabilities resulted in a reduction of approximately $5,843,000 which was fully offset by a change in the Company's valuation allowance. We have net operating loss carry-forwards for federal income tax purposes of $38,690,000 as of December 31, 2017. Included in these numbers are loss carry-forwards that were obtained through the acquisition of BioSeq, Inc. and are subject to Section 382 NOL limitations. These net operating loss carry-forwards expire at various dates from 2018 through 2038. We have net operating loss carry-forwards for state income tax purposes of approximately $31,735,000 at December 31, 2017. These net operating loss carry-forwards expire at various dates from 2030 through 2038. We have research and development tax credit carry-forwards for federal income tax purposes of approximately $1,089,000 as of December 31, 2017 and research and development tax credit carry-forwards for state income tax purposes of approximately $232,000 as of December 31, 2017. The federal credit carry-forwards expire at various dates from 2018 through 2038. The state credit carry-forwards expire at various dates from 2023 through 2033. In addition, we have federal alternative minimum tax credit carry-forwards for federal income tax purposes of approximately $217,000 as of December 31, 2017. These credits do not expire. Our effective income tax (benefit) provision rate was different than the statutory federal income tax (benefit) provision rate as follows for the years ended December 31: 2017 2016 Federal tax provision rate 35 % 34 % Permanent differences (0 )% 24 % State tax expense 0 % 0 % Refundable AMT and R&D tax credit 0 % 0 % Net operating loss carry back 0 % 0 % Valuation allowance (35 )% (58 )% Effective income tax provision 0 % 0 %

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(8) Commitments and Contingencies Operating Leases Our corporate office is currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying $6,950 per month, on a lease extension, signed on December 29, 2017, that expires December 31, 2018, for our corporate office. We expanded our space to include offices, warehouse and a loading dock on the first floor starting May 1, 2017 with a monthly rent increase already reflected in the current payments. We extended our lease for our space in Medford, MA to December 30, 2020. The lease requires monthly payments of $6,912.75 subject to annual cost of living increases. The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term. Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2017: 2018 $ 166,353 2019 82,953 2020 82,953 Thereafter - Total minimum payments required $ 332,259 Royalty Commitments BioMolecular Assays, Inc. In 1996, we acquired our initial equity interest in BioSeq, Inc., which at the time was developing our original pressure cycling technology. BioSeq, Inc. acquired its pressure cycling technology from BioMolecular Assays, Inc. under a technology transfer and patent assignment agreement. In 1998, we purchased all of the remaining outstanding capital stock of BioSeq, Inc., and at such time, the technology transfer and patent assignment agreement was amended to require us to pay BioMolecular Assays, Inc., a 5% royalty on our sales of products or services that incorporate or utilize the original pressure cycling technology that BioSeq, Inc. acquired from BioMolecular Assays, Inc. We are also required to pay BioMolecular Assays, Inc. 5% of the proceeds from any sale, transfer or license of all or any portion of the original pressure cycling technology. These payment obligations terminated on March 7, 2016. During the year ended December 31, 2016, we incurred approximately $6,963 in royalty expense associated with our obligation to BioMolecular Assays, Inc. In connection with our acquisition of BioSeq, Inc., we licensed certain limited rights to the original pressure cycling technology back to BioMolecular Assays, Inc. This license is non-exclusive and limits the use of the original pressure cycling technology by BioMolecular Assays, Inc. solely for molecular applications in scientific research and development and in scientific plant research and development. BioMolecular Assays, Inc. is required to pay us a royalty equal to 20% of any license or other fees and royalties, but not including research support and similar payments, it receives in connection with any sale, assignment, license or other transfer of any rights granted to BioMolecular Assays, Inc. under the license. BioMolecular Assays, Inc. was required to pay us these royalties until the expiration in March 2016 of the patents held by BioSeq, Inc. since 1998. We have not received any royalty payments from BioMolecular Assays, Inc. under this license. Battelle Memorial Institute In December 2008, we entered into an exclusive patent license agreement with the Battelle Memorial Institute (“ Battelle Target Discovery Inc . In March 2010, we signed a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (“ TDI TDI reagents In April 2012, we signed a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology. We recorded $30,000 and $20,000 of minimum royalty income in 2017 and 2016, respectively. We executed an amendment to this agreement on October 1, 2016 wherein we agreed to pay a monthly fee of $1,400 for the use of a lab bench, shared space and other utilities, and $2,000 per day for technical support services as needed. Severance and Change of Control Agreements Each of Mr. Schumacher, and Drs. Ting, Lazarev, and Lawrence, executive officers of the Company, are entitled to receive a severance payment if terminated by us without cause. The severance benefits would include a payment in an amount equal to one year of such executive officer’s annualized base salary compensation plus accrued paid time off. Additionally, the officer will be entitled to receive medical and dental insurance coverage for one year following the date of termination. Each of these executive officers, other than Mr. Schumacher, is entitled to receive a change of control payment in an amount equal to one year of such executive officer’s annualized base salary compensation, accrued paid time off, and medical and dental coverage, in the event of a change of control of the Company. In the case of Mr. Schumacher, this payment would be equal to two years of annualized base salary compensation, accrued paid time off, and two years of medical and dental coverage. The severance payment is meant to induce the aforementioned executives to remain in the employ of the Company, in general; and particularly in the occurrence of a change in control, as a disincentive to the control change.

Convertible Debt and Other Debt

Convertible Debt and Other Debt	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Convertible Debt and Other Debt	(9) Convertible Debt and Other Debt Senior Secured Convertible Debentures and Warrants We entered into Subscription Agreements (the “ Subscription Agreement Purchaser Debentures Warrants Purchase Price The Company issued a principal aggregate amount of $6,962,504 in Debentures which includes a 10% original issue discount on the Purchase Price. The Debenture does not accrue any additional interest during the first year it is outstanding but accrues interest at a rate equal to 10% per annum for the second year it is outstanding. The Debenture has a maturity date of two years from issuance. The Debenture is convertible any time after its issuance date. The Purchaser has the right to convert the Debenture into shares of the Company’s common stock at a fixed conversion price equal to $8.40 per share, subject to applicable adjustments. In the second year that the Debenture is outstanding, any interest accrued shall be payable quarterly in either cash or common stock, at the Company’s discretion. On various dates for the year ended December 31, 2017, the Company issued 61,307 shares of common stock based on the 10-day VWAP prior to quarter end to holders of the Debentures in payment of the quarterly interest accrued from the Debentures first anniversary date through June 30, 2017 for an aggregate amount of $483,054. We recognized a $218,452 gain on extinguishment of debt by calculating the difference of the shares valued on the issuance date and the amount of accrued interest through June 30, 2017. At any time after the Issuance Date, the Company has the option, subject to certain conditions, to redeem some or all of the then outstanding principal amount of the Debenture for cash in an amount equal to the sum of (i) 120% of the then outstanding principal amount of the Debenture, (ii) accrued but unpaid interest and (iii) any liquidated damages and other amounts due in respect of the Debenture. On September 11, 2017, we notified Debenture holders that their Debentures will be extended 180 days beyond the original maturity date as permitted in the Debenture agreement. We will continue to pay interest on the Debentures until the extended maturity date. We accounted for the Debenture extensions as debt modifications and not extinguishment of debt since the changes in fair value are not substantial in accordance with ASC 470-50. We started amortizing the remaining unamortized discount as of September 11, 2017 over the new term, which extends 180 days beyond the original maturity date. The Company issued warrants exercisable into a total of 376,759 shares of our common stock. The Warrants issued in this transaction are immediately exercisable at an exercise price of $12.00 per share, subject to applicable adjustments including full ratchet anti-dilution in the event that we issue any securities at a price lower than the exercise price then in effect. The Warrants have an expiration period of five years from the original issue date. The Warrants are subject to adjustment for stock splits, stock dividends or recapitalizations and also include anti-dilution price protection for subsequent equity sales below the exercise price. Subject to the terms and conditions of the Warrants, at any time commencing six months from the Final Closing, the Company has the right to call the Warrants for cancellation if the volume weighted average price of its Common Stock on the OTCQB (or other primary trading market or exchange on which the Common Stock is then traded) equals or exceeds three times the per share exercise price of the Warrants for 15 out of 20 consecutive trading days. In connection with the Subscription Agreement and Debenture, the Company entered into Security Agreements with the Purchasers whereby the Company agreed to grant to Purchasers an unconditional and continuing, first priority security interest in all of the assets and property of the Company to secure the prompt payment, performance and discharge in full of all of Company’s obligations under the Debentures, Warrants and the other Transaction Documents. The Company determined that the conversion feature of the Debentures met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature on each debt agreement and accounted for it as a derivative liability. The fair value of the conversion feature was accounted for as a note discount and is amortized to interest expense over the life of the loan. The fair value of the conversion feature was reflected in the conversion option liability line in the consolidated balance sheet as of December 31, 2016. The proceeds from these convertible debts were allocated between the host debt instrument and the convertible option based on the residual method. The estimated fair value of the convertible option was determined using a binomial formula, resulting in allocations to the convertible option and accounted for as a liability in the Company’s consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds are offset by debt discounts, which are amortized to interest expense over the expected life of the debt. ASC 470-20 states that the proceeds from the issuance of debt with detachable stock warrants should be allocated between the debt and warrants on the basis of their relative fair market values. The debt discount will be amortized to interest expense over the two-year term of these loans. We amortized $3,740,746 of the debt discount to interest expense in 2016. The warrants issued in connection with the convertible debentures are classified as warrant derivative liabilities because the warrants are entitled to certain rights in subsequent financings and the warrants contain “down-round protection” and therefore, do not meet the scope exception for treatment as a derivative under ASC 815, Derivatives and Hedging, (“ASC 815”). Since “down-round protection” is not an input into the calculation of the fair value of the warrants, the warrants cannot be considered indexed to the Company’s own stock which is a requirement for the scope exception as outlined under ASC 815. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of $2,847,624 to the total warrants out of the gross proceeds of $6,329,549. The fair value will be affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. We early adopted ASU 2017-11 and applied the guidance to derivative accounting. We reclassified the fair value of the warrant derivative liabilities to stockholders’ equity when we adopted ASU 2017-11. Other convertible notes On May 13, 2016, one lender converted an outstanding note issued on April 28, 2015 and the related accrued interest totaling $117,837 to 14,028 common shares. As of December 31, 2017, the outstanding balance on the note was zero. On May 24, 2016, we sold an additional convertible note for $107,000 with warrants to purchase 1,667 shares of common stock at an exercise price of $16.50 per share. The purchaser has the right to convert the notes into shares of the Company’s common stock at a fixed conversion price equal to $13.50 per share, subject to applicable adjustments. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of $12,406 to the total warrants and the recognition of a beneficial conversion feature of $7,962, both of which were recorded as a discount to the note. We evaluated the convertible note and warrants for derivative liability treatment and determined that these instruments do not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that this financing arrangement did not qualify for derivative accounting treatment. The loan was paid in full in fiscal year 2016. On June 14, 2016, we sold an additional convertible note for $115,000 and issued 1,023 common shares to compensate the lender. On July 1, 2016, the note was modified to increase the principal amount to $200,000 and we received the remaining proceeds of $85,000 on the same date and issued 1,144 common shares as compensation to the lender. The lender has the right to convert the note into shares of the Company’s common stock at fixed conversion price equal to $13.50 per share, subject to applicable adjustments. We valued the total 2,167 common shares using the stock prices at the respective dates the note proceeds were received and recorded the relative fair value of the shares amounting to $26,000 as a debt discount to be amortized over the term of the loan. We then computed the effective conversion price of the note, noting that no beneficial conversion feature exists. We also evaluated the convertible note for derivative liability treatment and determined that the instrument does not include certain rights such as price protection like our previous debt financing. Accordingly, we concluded that this financing arrangement did not qualify for derivative accounting treatment. The loan was paid in full in fiscal year 2017. On July 29, 2016, we sold an additional convertible note for $100,000 and issued 1,084 common shares to compensate the lender. The lender has the right to convert the notes into shares of the Company’s common stock at a fixed conversion price equal to $13.50 per share, subject to applicable adjustments. The proceeds were allocated between the convertible note and shares of common stock based on their relative fair values. The relative fair values of the convertible note and the common shares was $87,241 and $12,759, respectively. We then computed the effective conversion price of the note, noting that the convertible debt gave rise to a beneficial conversion feature (BCF) of $12,759. The sum of the relative fair value of the common shares and the BCF of $25,518 was recorded as a debt discount to be amortized over the term of the loan. We also evaluated the convertible note for derivative liability treatment and determined that the instruments does not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that this financing arrangements did not qualify for derivative accounting treatment. The loan was paid in full in fiscal year 2017. On September 15, 2016, we sold an additional convertible note for $500,000 and issued 6,666 common shares to compensate the lender. The lender has the right to convert the notes into shares of the Company’s common stock at a fixed conversion price equal to $13.50 per share, subject to applicable adjustments. The convertible note includes an original issue discount of $40,541 and is subject to a one-time interest of 9% or $45,000 which was recorded as a debt discount and amortized over the term of the loan. The proceeds were allocated between the convertible note and shares of common stock based on their relative fair values. The relative fair value of the convertible note was $434,028. The allocation of the gross proceeds to the shares of common stock was $65,972 and recorded as a debt discount to be amortized over the term of the loan. We then computed the effective conversion price of the note, noting that no beneficial conversion feature exists. We also evaluated the convertible note for derivative liability treatment and determined that the instrument does not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that this financing arrangement did not qualify for derivative accounting treatment. The loan was paid in full in fiscal year 2017. On various dates during the quarter ended December 31, 2017, the Company issued convertible notes for net proceeds of $1,755,850 with the following terms: a) maturity ranging from 3 to 12 months; b) annual interest rates ranging from 5% to 12%; c) convertible to the Company’s common stock at issuance at a fixed rate of $7.50 or convertible at variable conversion rates either after 6 months after issuance or in the event of a default. Certain of these notes were issued with shares or warrants which were fair valued at issuance dates. The relative fair values of the shares or warrants issued with the notes were recorded as a debt discount and amortized over the term of the notes. We then computed the effective conversion price of the notes, noting that no beneficial conversion feature exists. We also evaluated the convertible notes for derivative liability treatment and determined that the notes did not qualify for derivative accounting treatment as of December 31, 2017. The specific terms of the convertible notes and outstanding balances as of December 31, 2017 are listed in the tables below. Convertible Notes Inception Date Term Loan Amount Outstanding Balance Original Issue Discount Interest Rate Conversion Price(Convertible at Inception Date) Deferred Finance Fees Discount related to fair value of conversion feature and warrants/shares July 22, 2015 30 months 1 $ 2,180,000 $ 2,180,000 $ 218,000 2 10 % 3 $ 8.40 $ 388,532 $ 2,163,074 September 25, 2015 30 months 1 1,100,000 1,100,000 110,000 2 10 % 3 $ 8.40 185,956 1,022,052 October 2, 2015 30 months 1 150,000 150,000 15,000 2 10 % 3 $ 8.40 26,345 140,832 October 6, 2015 30 months 1 30,000 30,000 3,000 2 10 % 3 $ 8.40 5,168 26,721 October 14, 2015 30 months 1 50,000 50,000 5,000 2 10 % 3 $ 8.40 8,954 49,377 November 2, 2015 30 months 1 250,000 250,000 25,000 2 10 % 3 $ 8.40 43,079 222,723 November 10, 2015 30 months 1 50,000 50,000 5,000 2 10 % 3 $ 8.40 8,790 46,984 November 12, 2015 30 months 1 215,000 215,000 21,500 2 10 % 3 $ 8.40 38,518 212,399 November 20, 2015 30 months 1 200,000 200,000 20,000 2 10 % 3 $ 8.40 37,185 200,000 December 4, 2015 30 months 1 170,000 170,000 17,000 2 10 % 3 $ 8.40 37,352 170,000 December 11, 2015 30 months 1 360,000 360,000 36,000 2 10 % 3 $ 8.40 75,449 360,000 December 18, 2015 30 months 1 55,000 55,000 5,500 2 10 % 3 $ 8.40 11,714 55,000 December 31, 2015 30 months 1 100,000 100,000 10,000 2 10 % 3 $ 8.40 20,634 100,000 January 11, 2016 30 months 1 100,000 100,000 10,000 2 10 % 3 $ 8.40 24,966 80,034 January 20, 2016 30 months 1 50,000 50,000 5,000 2 10 % 3 $ 8.40 9,812 40,188 January 29, 2016 30 months 1 300,000 300,000 30,000 2 10 % 3 $ 8.40 60,887 239,113 February 26, 2016 30 months 1 200,000 200,000 20,000 2 10 % 3 $ 8.40 43,952 156,048 March 10, 2016 30 months 1 125,000 125,000 12,500 2 10 % 3 $ 8.40 18,260 106,740 March 18, 2016 30 months 1 360,000 360,000 36,000 2 10 % 3 $ 8.40 94,992 265,008 March 24, 2016 30 months 1 106,667 106,667 10,667 2 10 % 3 $ 8.40 15,427 91,240 March 31, 2016 30 months 1 177,882 177,882 17,788 2 10 % 3 $ 8.40 2,436 175,446 June 15, 2016 6 months 40,000 - - 12 % $ 13.50 - 3,680 June 17, 2016 6 months 40,000 - - 12 % $ 13.50 - 3,899 June 22, 2016 6 months 35,000 - - 12 % $ 13.50 - 3,373 July 6, 2016 6 months 85,000 - - 12 % $ 13.50 - 15,048 July 29, 2016 6 months 100,000 - - 12 % $ 13.50 - 25,518 September 15, 2016 8 months 500,000 - 85,541 9 % $ 13.50 - 65,972 October 11, 2017 12 months 85,000 - - 5 % - 4,250 - October 20, 2017(4) 12 months 150,000 150,000 - 5 % $ 7.50 7,500 - October 25, 2017 6 months 103,000 103,000 - 12 % - 3,000 October 27, 2017 12 months 170,000 170,000 - 5 % - 4,250 10,000 November 13, 2017 9 months 380,000 380,000 15,200 8 % $ 7.50 15,200 46,274 November 22, 2017 12 months 100,000 100,000 10,000 5 % - 2,000 - November 28, 2017 10 months 103,000 103,000 3,000 12 % - - - November 29, 2017 6 months 150,000 150,000 - 15 % $ 7.50 - 15,200 November 30, 2017 3 months 50,000 50,000 8 % $ 7.50 December 5, 2017 3 months 52,500 52,500 - 10 % $ 7.50 2,500 - December 6, 2017 4 months 100,000 100,000 - 10 % $ 7.50 - - December 11, 2017 6 months 130,000 130,000 1,500 5 % - 6,500 6,460 December 19, 2017 6 months 110,000 110,000 1,500 5 % - 5,500 5,775 December 28, 2017 6 months 55,000 55,000 - 15 % $ 7.50 5,000 - December 29, 2017 12 months 105,000 105,000 - 5 % - 5,000 - $ 8,973,049 $ 8,088,049 $ 749,696 $ 1,219,108 $ 6,124,178 1) The loan term was extended by 180 days and further extended on January 15, 2018 by 60 days to repay in common stock. The July 22, 2015 Debentures of $2,180,000 is currently past due as of March 19, 2018. 2. The original issue discount is reflected in the first year. 3. The annual interest started accruing in the second year. 4. On October 20, 2017, Company issued to EMA Financial, LLC a 5% one year convertible note in the amount of $150,000, less $7,500 from OID and fees. The note is convertible at $7.50 per share, provided however, if the Company fails to comply with Section 1.9 of the note then the conversion price shall be 65% of the lowest sale price for the Common Stock on the Principal Market during the twenty (20) consecutive Trading Days immediately preceding the Conversion Date or the closing bid price, whichever is lower. As of December 31, 2017, a total of approximately $291,000 convertible debentures were purchased by related parties who were members of the Company’s Board of Directors and management and their family members. Deferred finance fees included cash commissions amounting to $621,500 and the fair value of the 2,101,786 warrants issued to the placement agent amounting to $536,908. For the year ended December 31, 2017, the Company recognized amortization expense related to the debt discounts indicated above of $1,955,193. The unamortized debt discounts as of December 31, 2017 related to the convertible debentures and other convertible notes amounted to $433,228. Revolving Note Payable On October 28, 2016, an accredited investor (the “ Investor Revolving Note Maturity Date The Revolving Note was amended on May 2, 2017 to increase the aggregate principal amount to $3,000,000, to issue 16,667 shares of our Common Stock to the Investor, to decrease the exercise price per share of the warrants to the lower of (i) $12.00 or (ii) the per share purchase price of the shares of our Common Stock sold in the Qualified Offering, and to change the references in the Revolving Note from “the six (6) month anniversary of October 28, 2016” to “July 25, 2017.” The fair value of the 16,667 shares issued of $149,018 was accounted for as a note discount and are amortized to interest expense over the life of the loan. We evaluated the accounting impact of the Revolving Note amendment and deemed that the amendment did not have a material impact on our consolidated financial statements. The Revolving Note was further amended on August 18, 2017 to increase the aggregate principal amount to $3,500,000 with all other terms unchanged. In the event that a Qualified Offering had occurred after July 25, 2017, but prior to the Maturity Date, within seven (7) Business Days of the closing of the Qualified Offering, the Company was to pay a cash fee equal to five percent (5%) of the total outstanding amount owed by the Company to the Holder as of the closing date of the Qualified Offering or, at the option of the Company, issue to the Holder a number of restricted shares of the Company’s common stock equal to (x) five percent (5%) of the total outstanding amount owed by the Company to the Holder as of the closing date of the Qualified Offering divided by (y) the purchase price provided by the documents governing the Qualified Offering. A Qualified Offering In the event that a Qualified Offering had not occurred after July 25, 2017, but prior to the Maturity Date, within seven (7) Business Days of the closing of the Qualified Offering, the Company shall pay a cash fee equal to five percent (5%) of the total outstanding amount owed by the Company to the Holder or, at the option of the Company, issue to the Holder a number of restricted shares of the Company’s common stock equal to (x) five percent (5%) of the total outstanding amount owed by the Company to the Holder as of the Maturity Date divided by (y) the VWAP of the Company’s common stock for the last ten trading days preceding the Maturity Date. A Qualified Offering did not occur on or prior to the Maturity Date. Interest on the principal balance of the Revolving Note shall be paid in full on the Maturity Date, unless otherwise paid prior to the Maturity Date. Interest shall be assessed as follows: (i) a one-time interest of 10% on all principal amounts advanced prior to April 28, 2017; (ii) the foregoing and 4% on any amount remaining outstanding if the principal amount is repaid between April 28, 2017 and July 28, 2017; or (iii) both of the foregoing and 4% on any amount remaining outstanding if the principal amount is repaid between July 28, 2017 and October 28, 2017. Broker fees amounting to $296,500, the one-time interest of $350,000 and the relative fair value of the 291,667 warrants issued to the Investor amounting to $1,148,275 were recorded as debt discounts and amortized over the term of the revolving note. The unamortized debt discounts related to the Revolving Note were fully amortized as of December 31, 2017. The Revolving Note was still outstanding as of December 31, 2017 and is currently past due. We continue to accrue interest on the note. The following table provides a summary of the changes in convertible debt and revolving note payable, net of unamortized discounts, during 2017: 2017 Balance at January 1, $ 5,273,937 Adjustment due to ASU 2017-11 923,468 Issuance of convertible debt, face value 4,093,500 Deferred financing cost (267,650 ) Debt discount related to one-time interest charge (225,000 ) Debt discount from incentive shares to increase the Revolving Note aggregate principal limit (150,000 ) Debt discount from shares and warrants issued with the notes (750,705 ) Payments (925,541 ) Accretion of interest and amortization of debt discount to interest expense through December 31, 3,815,767 Balance at December 31, 11,787,776 Less: current portion 11,787,776 Convertible debt, long-term portion $ - Other Notes On January 20, 2016 we borrowed $50,000 from an individual with no interest or fees. We paid back the loan in March 2016. On February 8, 2016 we signed a Merchant Agreement with a lender. Under the agreement we received $100,000 in exchange for third position rights to all customer receipts until the lender is paid $129,900, which is collected at the rate of $927 per business day. The Company paid $2,000 in fees in connection with this loan. We received an additional $125,000 in June 2016 under the existing Merchant Agreement of which $48,420 was used to pay off the prior loan. The lender provided an additional $70,000 on August 16, 2016. As of December 31, 2017, the outstanding balance on this note was zero. On May 9, 2016 we signed a promissory note with a lender. Under the agreement we received $200,000 net of a $6,000 original issue discount and we repaid $206,000 on August 25, 2016. In connection with this promissory note, we issued warrants exercisable into 3,333 shares of our common stock. The warrants issued in this transaction are immediately exercisable at an exercise price of $16.50 per share. The warrants have an expiration period of three years from the original issue date. The warrants are subject to adjustment for stock splits, stock dividends or recapitalizations. The warrants were recorded as a component of our Stockholders’ Equity. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of $27,349 to the total warrants and recorded as a discount to the note to be amortized over the term of the loan. We evaluated the warrants for derivative liability treatment and determined that these instruments do not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that these instruments did not qualify for derivative accounting treatment. In August 2016, the lender extended the maturity date of the note from August 11, 2016 to August 25, 2016. Consequently, a penalty interest of $41,200 was added to the principal amount and settled through the issuance of 3,335 common shares. As of December 31, 2016, the outstanding balance on this note was zero. On February 15, 2017, we received six-month, non-convertible loans in the aggregate of $220,000 from two accredited investors. We agreed to issue each investor 5,667 shares of restricted common stock. The loans earn no interest but carry a 10% original issue discount fee. We recorded the fair value of the shares amounting to $43,616 as debt discounts that will be amortized to interest expense during the term of the loans. We received a one-month extension on one loan and two one-month extensions on the other. Each extension required a 10% fee to the lender. We treated these extensions as loan extinguishments and accordingly wrote off the original debt and recorded new debt to include the extension fees as part of the principal amount. The extension fees of $33,000 to extend the loans were recorded as losses on extinguishment of debt in the consolidated financial statements. Both loans were paid off entirely by October 31, 2017. We amortized the entire $63,616 of debt discounts in the year ended December 31, 2017. On March 14, 2017, we received an eight-month, non-convertible loan of $250,000 from a privately-held investment firm. The loan earned an annual interest rate of 10% and included a 10% original issue discount. We also agreed to issue the investor 8,333 shares of restricted common stock. We recorded the fair value of the shares amounting to $46,748 as a debt discount that will be amortized to interest expense during the term of the loan. We amortized the entire $76,748 of the debt discount in the year ended December 31, 2017. In the event of default and at the option of the holder, the loan was convertible into common stock at a 35% discount to the lowest closing stock price for the 15 trading days prior to conversion. We paid the loan entirely by the maturity date so derivative accounting was triggered from the conversion option. On March 21, 2017, we received an eight-month, non-convertible loan of $170,000 from an accredited investor. The loan earns an annual interest rate of 10% and includes a 10% original issue discount. We also agreed to issue the investor 5,667 shares of restricted common stock. We recorded the fair value of the shares amounting to $35,079 as a debt discount that will be amortized to interest expense during the term of the loan. The loan still remains outstanding as of December 31, 2017 with a balance of $170,000. The lender extended the term to December 31, 2017 and further to March 31, 2018 in exchange for a total of 9,500 shares of common stock. We amortized $44,841 of debt discounts in the year ended December 31, 2017. The unamortized debt discount as of December 31, 2017 was $7,238. On April 19, 2017, we received a 7-month non-convertible loan of $250,000 from a privately-held investment firm. The loan earned an annual interest rate of 10% and included a 10% original issue discount. We agreed to issue 833 shares at closing. Until the loan was repaid, we agreed that over the next one hundred eighty (180) days to issue 2,500 shares to the Investor every sixty (60) days for a total issuance of 8,333 shares. We recorded the fair value of the 8,333 shares amounting to $43,687 as a debt discount that was amortized to interest expense during the term of the loan. We amortized $68,687 of debt discounts in the year ended December 31, 2017. The unamortized debt discount as of December 31, 2017 was zero. In the event of default and at the option of the holder, the loan was convertible into common stock at a 35% discount to the lowest closing stock price for the 15 trading days prior to conversion. We paid the loan entirely by the maturity date so derivative accounting was triggered from the conversion option. On May 19, 2017, we received a 45-day non-convertible loan of $630,000 from a private investor. The loan provides guaranteed interest of $63,000 and has an origination fee of $32,000. We paid a broker $31,500 in connection with this loan. The unamortized debt discount as of December 31, 2017 was zero. We used these proceeds to pay off in full our September 2016 loan of $589,189. The loan remains outstanding and is currently past due. We continue to accrue interest at a 20% annual rate from the maturity date. On August 1, 2017, we signed a non-convertible installment loan with a lender. Under the agreement we received a loan of $75,000 with a weekly repayment of $3,500 until payment in full. The loan includes $18,750 representing an original issue discount, interest and fees resulting in a total payable of $93,750. The loan remains outstanding as of December 31, 2017 with a balance of approximately $16,750. On September 12, 2017, we received a 9-month non-convertible loan of $225,000 from a privately-held investment firm. The loan earns an annual interest rate of 10%. The Company paid total fees of $25,000 including original issue discount and other costs related to this loan. We agreed to issue 3,333 shares at closing. We recorded the fair value of the shares as a debt discount that will be amortized to interest expense during the term of the loan. We amortized $15,311 of debt discounts in the year ended December 31, 2017. The unamortized debt discount as of December 31, 2017 was $22,689. In the event of default and at the option of the holder, the loan is convertible into common stock at a 35% discount to the average of the two lowest daily volume weighted average closing stock price for the 20 trading days prior to conversion. Merchant Agreements We have signed various Merchant Agreements which entitle the lenders to our customer receipts. We accounted for the Merchant Agreements as loans under ASC 860 because while we provided rights to current and future receipts, we still had control over the receipts. The following table shows our Merchant Agreements as of December 31, 2017. Inception Date Purchase Price Purchased Amount Outstanding Balance Daily Payment Interest Rate Deferred Finance Fees Note January 6, 2016 250,000 322,500 $ - 1,279.76 14 % 2,500 1 February 8, 2016 100,000 129,900 - 927.00 15 % 2,000 August 16, 2016 70,000 90,930 - 650.00 15 % 1,590 August 26, 2016 125,000 166,250 - 1,386.00 6 % 2,535 February 6, 2017 125,000 161,250 - 1,343.75 15 % 1,250 March 2, 2017 75,750 97,718 - 775.74 7 % 750 June 6, 2017 250,000 330,000 - 1,833.00 5 % 6,250 June 21, 2017 150,000 190,500 - 1,361.00 15 % 1,498 July 17, 2017 125,000 160,000 - 1,250.00 7 % 1,250 September 29, 2017 75,000 102,000 (1,200 ) 1,200.00 15 % 1,500 October 25, 2017 110,000 153,890 71,233 1,539.00 15 % 8,800 December 7, 2017 160,000 212,800 157,088 1,251.76 25 % 5,799 December 12, 2017 160,000 212,800 159,186 1,251.76 15 % 5,258 $ 1,775,750 $ 2,330,538 $ 386,307 $ 40,980 1) The Company recognized a gain in fiscal year 2016 on the settlement of the previous loan of $5,044 which was credited to interest expense. We amortized $312,870 and $40,802 of debt discounts during the years ended December 31, 2017 and 2016, respectively for all non-convertible notes. The total unamortized discount for all non-convertible notes as of December 31, 2017 was $48,194. Related Party Notes During the year ended December 31, 2016, the Company received advances from certain officers of the Company amounting to $20,000. These advances were non-interest bearing and payable on demand. As of December 31, 2016 there are no outstanding notes to related parties.

Stockholders' (Deficit)

Stockholders' (Deficit)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Stockholders' (Deficit)	(10) Stockholders’ (Deficit) Preferred Stock We are authorized to issue 1,000,000 shares of preferred stock with a par value of $0.01. Of the 1,000,000 shares of preferred stock: 1) 20,000 shares have been designated as Series A Junior Participating Preferred Stock (“ Junior A 2) 313,960 shares have been designated as Series A Convertible Preferred Stock (“ Series A 3) 279,256 shares have been designated as Series B Convertible Preferred Stock (“ Series B 4) 88,098 shares have been designated as Series C Convertible Preferred Stock (“ Series C 5) 850 shares have been designated as Series D Convertible Preferred Stock (“ Series D 6) 500 shares have been designated as Series E Convertible Preferred Stock (“Series E”) 7) 240,000 shares have been designated as Series G Convertible Preferred Stock (“ Series G 8) 10,000 shares have been designated as Series H Convertible Preferred Stock (“ Series H 9) 21 shares have been designated as Series H2 Convertible Preferred Stock (“ Series H2 10) 6,250 shares have been designated as Series J Convertible Preferred Stock (“ Series J 11) 15,000 shares have been designated as Series K Convertible Preferred Stock (“ Series K As of December 31, 2017 and 2016, there were no shares of Junior A, and Series A, B, C, and E issued and outstanding. Series D Convertible Preferred Stock On November 11, 2011, we completed a registered direct offering, pursuant to which we sold an aggregate of 843 units for a purchase price of $1,000 per unit, resulting in gross proceeds to us of $843,000 (the “ Series D Placement Series D Unit Series D Convertible Preferred Stock Series D Warrant The proceeds from the sale of each Series D Unit were allocated between the Series D Convertible Preferred Stock and the Series D Warrants based on the residual method. The estimated fair value of the Series D Warrants was determined using a binomial formula, resulting in an allocation of the gross proceeds of $283,725 to the total warrants issued. The allocation of the gross proceeds to the Series D Convertible Preferred Stock was $559,275. In accordance with the provisions of ASC 470-20, an additional adjustment between Additional Paid in Capital and Accumulated Deficit of $530,140 was recorded to reflect an implicit non-cash dividend related to the allocation of proceeds between the stock and warrants issued. The $530,140 represents the value of the adjustment to additional paid in capital related to the beneficial conversion feature of the Series D Convertible Preferred Stock. The value adjustment was calculated by subtracting the fair market value of the underlying common stock on November 10, 2011 issuable upon conversion of the Series D Convertible Preferred Stock from the fair market value of the Series D Convertible Preferred Stock as determined when the Company performed a fair market value allocation of the proceeds to the Series D Convertible Preferred Stock and warrants. The warrants are recorded as a liability. See “Warrant Derivative Liability” below. The Series D Convertible Preferred Stock will rank senior to the Company’s common stock and Series C Convertible Preferred Stock with respect to payments made upon liquidation, winding up or dissolution. Upon any liquidation, dissolution or winding up of the Company, after payment of the Company’s debts and liabilities, and before any payment is made to the holders of any junior securities, the holders of Series D Convertible Preferred Stock will first be entitled to be paid $1,000 per share subject to adjustment for accrued but unpaid dividends. We may not pay any dividends on shares of common stock unless we also pay dividends on the Series D Convertible Preferred Stock in the same form and amount, on an as-if-converted basis, as dividends actually paid on shares of our common stock. Except for such dividends, no other dividends may be paid on the Series D Convertible Preferred Stock. Each share of Series D Convertible Preferred Stock is convertible into 84 shares of common stock (based upon an initial conversion price of $19.50 per share) at any time at the option of the holder, subject to adjustment for stock splits, stock dividends, combinations, and similar recapitalization transactions (the “ Series D Conversion Ratio In addition, in the event we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares of common stock, then following such event, the holders of the Series D Convertible Preferred Stock will be entitled to receive upon conversion of the Series D Convertible Preferred Stock the same kind and amount of securities, cash or property which the holders of the Series D Convertible Preferred Stock would have received had they converted the Series D Convertible Preferred Stock immediately prior to such fundamental transaction. The holders of Series D Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except that the holders of Series D Convertible Preferred Stock may vote separately as a class on any matters that would (i) amend, our Restated Articles of Organization, as amended, in a manner that adversely affects the rights of the Series D Convertible Preferred Stock, (ii) alter or change adversely the powers, preferences or rights of the Series D Convertible Preferred Stock or alter or amend the certificate of designation, (iii) authorize or create any class of shares ranking as to dividends, redemption or distribution of assets upon liquidation senior to, or otherwise pari passu with, the Series D Convertible Preferred Stock, or (iv) increase the number of authorized shares of Series D Convertible Preferred Stock. If, within 12 months of the initial issuance of the Series D Convertible Preferred Stock, we issue any common stock, common stock equivalents, indebtedness or any combination thereof (a “ Subsequent Financing Series D Warrants The Series D Warrants originally had an exercise price equal to $24.30 per share of common stock. In April 2012, the number of Series D Warrants increased by 17,681 to a total of 34,930 and each Series D Warrant had an exercise price reset to $12.00 per share of common stock. In December of 2013 the number of Series D Warrants increased by 20,958 to a total of 55,887 and each Series D Warrant had an exercise price reset to $7.50 per share of common stock. The Series D Warrants will be exercisable beginning on the six-month anniversary of the date of issuance and expire five years from the initial exercise date. The Series D Warrants permit the holder to conduct a “cashless exercise” at any time a registration statement registering, or the prospectus contained therein, is not available for the issuance of the shares of common stock issuable upon exercise of the Series D Warrant, and under certain circumstances at the expiration of the Series D Warrants. The exercise price and/or number of shares of common stock issuable upon exercise of the Series D Warrants are subject to adjustment for certain stock dividends, stock splits or similar capital reorganizations, as set forth in the Warrants. The exercise price is also subject to adjustment in the event that we issue any shares of common stock or common stock equivalents at a per share price that is lower than the exercise price for the Series D Warrants then in effect. Upon any such issuance, subject to certain exceptions, the exercise price will be reduced to the per share price at which such shares of common stock or common stock equivalents are issued and number of Series D Warrant shares issuable thereunder shall be increased such that the aggregate exercise price payable thereunder, after taking into account the decrease in the exercise price, shall be equal to the aggregate exercise price prior to such adjustment. Unless waived under certain circumstance by the holder of a Series D Warrant, such holder may not exercise the Series D Warrant if upon such exercise the holder’s beneficial ownership of the Company’s common stock would exceed certain thresholds. In the event we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares of common stock, then following such event, the holders of the Series D Warrants will be entitled to receive upon exercise of the Series D Warrants the same kind and amount of securities, cash or property which the holders would have received had they exercised the Series D Warrants immediately prior to such fundamental transaction. On May 10, 2017, we received net proceeds of $140,214 from the exercise of 19,889 stock purchase warrants from the Series D registered direct offering on November 10, 2011. In consideration for the warrant exercises, we issued to the investors warrants to purchase 39,778 shares of our Common Stock at an exercise price per share equal to $8.40 per share. The warrants expire on the third year anniversary date. We determined the fair value of $186,802 for these warrants and recorded the value as other expenses. Series G Convertible Preferred Stock On July 6 and November 15, 2012, we completed a private placement, pursuant to which we sold an aggregate of 4,844 units for a purchase price of $150.00 per unit (the “Series G Purchase Price”), resulting in gross proceeds to us of $726,600 (the “ Series G Private Placement Series G Unit Series G Warrant Each share of Series G Preferred Stock will receive a cumulative dividend at the annual rate of (i) four percent (4%) on those shares of Series G Preferred Stock purchased from the Company by an individual purchaser with an aggregate investment of less than $100,000, (ii) six percent (6%) on those shares of Series G Preferred Stock purchased from the Company by an individual purchaser with an aggregate investment of at least $100,000 but less than $250,000, and (iii) twelve percent (12%) on those shares of Series G Preferred Stock purchased from the Company by an individual purchaser with an aggregate investment of at least $250,000. Dividends accruing on the Series G Preferred Stock shall accrue from day to day until, and shall be paid within fifteen (15) days of, the first anniversary of, the original issue date of the Series G Preferred Stock; provided, however, if any shares of the Company’s Series E Preferred Stock are outstanding at such time, payment of the accrued dividends on the Series G Preferred Stock shall be deferred until no such shares of Series E Convertible Preferred Stock remain outstanding. The Company may pay accrued dividends on the Series G Preferred Stock in cash or in shares of its common stock equal to the volume weighted average price of the common stock as reported by the OTCQB for the ten (10) trading days immediately preceding the Series G’s first anniversary. At the election of the Company and upon required advanced notice, each share of Series G Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) if, after 6 months from the original issuance date of the Series G Preferred Stock, the common stock trades on the OTCQB (or other primary trading market or exchange on which the common stock is then traded) at a price equal to at least $22.50, for 7 out of 10 consecutive trading days with average daily trading volume of at least 334 shares, (ii) on or after the first anniversary of the original issuance date of the Series G Preferred Stock or (iii) upon completion of a firm-commitment underwritten registered public offering by the Company at a per share price equal to at least $22.50, with aggregate gross proceeds to the Company of not less than $2.5 million. Unless waived under certain circumstances by the holder of the Series G Preferred Stock, such holder’s Series G Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. The holders of Series G Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law. Series G Warrants The Series G Warrants issued in the Series G Private Placement had an exercise price equal to $15.00 per share and expired on July 6, 2015. Series H Convertible Preferred Stock On December 28, 2012 the Company amended the Articles of Incorporation to authorize 10,000 shares of Series H Convertible Preferred Stock. On January 4, 2013, the Company reported that it had entered into a securities purchase and exchange agreement with an investor, pursuant to which the Company agreed to exchange 33,334 shares of the Company’s common stock, par value $0.01 per share of common stock held by the investor for an aggregate of 10,000 shares of a newly created series of preferred stock, designated Series H Convertible Preferred Stock, par value $0.01 per share (the “ Series H Preferred Stock Series H2 Convertible Preferred Stock On December 23, 2014 the Company amended the Articles of Incorporation to authorize 21 shares of Series H2 Convertible Preferred Stock. On December 23, 2014, the Company reported that it had entered into a securities purchase and exchange agreement with an investor, pursuant to which the Company agreed to exchange 70,000 shares of the Company’s common stock, par value $0.01 per share of common stock held by the investor for an aggregate of 21 shares of a newly created series of preferred stock, designated Series H2 Convertible Preferred Stock, par value $0.01 per share (the “ Series H2 Preferred Stock Series J Convertible Preferred Stock On February 6, March 28 and May 20, 2013, the Company entered into a Securities Purchase with various individuals pursuant to which the Company sold an aggregate of 5,087.5 units for a purchase price of $400.00 per unit (the “Purchase Price”), or an aggregate Purchase Price of $2,034,700. Each unit purchased in the initial tranche consists of (i) one share of a newly created series of preferred stock, designated Series J Convertible Preferred Stock, par value $0.01 per share (the “Series J Convertible Preferred Stock”), convertible into 34 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 34 shares of common stock at an exercise price equal to $12.00 per share. The warrants expire three years from the issuance date. From the date of issuance of any shares of Series J Convertible Preferred Stock and until the earlier of the first anniversary of such date, the voluntary conversion of any shares of Series J Convertible Preferred Stock, or the date of any mandatory conversion (solely under the Company’s control based upon certain triggering events) of the Series J Convertible Preferred Stock, dividends will accrue on each share of Series J Convertible Preferred Stock at an annual rate of (i) four percent (4%) of the Purchase Price on those shares of Series J Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased from the Company shares of Series J Convertible Preferred Stock with an aggregate Purchase Price of less than $250,000, and (ii) six percent (6%) of the Purchase Price on those shares of Series J Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased shares of Series J Convertible Preferred Stock with an aggregate purchase price of at least $250,000. Dividends accruing on the Series J Convertible Preferred Stock shall accrue from day to day until the earlier of the first anniversary of the date of issuance of such shares of Series J Convertible Stock, the voluntary conversion of any shares of Series J Convertible Preferred Stock, or the date of any mandatory conversion of the Series J Convertible Preferred Stock, and shall be paid, as applicable, within fifteen (15) days of the first anniversary of the original issue date of the Series J Convertible Preferred Stock, within five (5) days of the voluntary conversion of shares of the Series J Convertible Preferred Stock, or within five (5) days of the mandatory conversion of shares of the Series J Convertible Preferred Stock. The Company may pay accrued dividends on the Series J Convertible Preferred Stock in cash or, in the sole discretion of the Board of Directors of the Company, in shares of its common stock in accordance with a specified formula. Each share of Series J Convertible Preferred Stock is convertible into 34 shares of common stock at the option of the holder on or after the six-month anniversary of the issuance of such share, subject to adjustment for stock splits, stock dividends, recapitalizations and similar transactions (the “Conversion Ratio”). Unless waived under certain circumstances by the holder of Series J Convertible Preferred Stock, such holder’s shares of Series J Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. At the election of the Company and upon required advance notice, each share of Series J Convertible Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) on or after the six-month anniversary of the original issuance date of the Series J Convertible Preferred Stock, the common stock trades on the OTCQB (or other primary trading market or exchange on which the common stock is then traded) at a price per share equal to at least $24.00 for 7 out of 10 consecutive trading days with average daily trading volume of at least 1,667 shares, (ii) on the first anniversary of the original issuance date of the Series J Convertible Preferred Stock or (iii) within three days of the completion of a firm-commitment underwritten registered public offering by the Company at a per share price equal to at least $24.00, with aggregate gross proceeds to the Company of not less than $2.5 million. Unless waived under certain circumstances by the holder of the Series J Convertible Preferred Stock, such holder’s Series J Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. The holders of Series J Convertible Preferred Stock are not entitled to vote on any matters presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), except as required by law. Series J Warrants The Series J Warrants issued in the Series J Private Placement had an exercise price equal to $12.00 per share and expired on February 6, March 28 and May 20, 2016. Registration Rights Agreement In connection with the Private Placement, the Company has agreed that, if, at any time after February 1, 2014, the Company files a Registration Statement relating to an offering of equity securities of the Company (the “Registration Statement”), subject to certain exceptions, including a Registration Statement relating solely to an offering or sale of securities having an aggregate public offering price of less than $5,000,000, the Company shall include in the Registration Statement the resale of the shares of common stock underlying the Warrants. Shares of common stock issued upon conversion of Series J Convertible Preferred Stock or in payment of the dividend on the Series J Convertible Preferred Stock will not be registered and will not be subject to registration rights. This right is subject to customary conditions and procedures. Series K Convertible Preferred Stock On December 12, 2013, the Company entered into a Securities Purchase with various individuals pursuant to which the Company sold an aggregate of 4,000 units for a purchase price of $250.00 per unit (the “Purchase Price”), for an aggregate Purchase Price of $1,000,000. Each unit purchased in the initial tranche consists of (i) one share of a newly created series of preferred stock, designated Series K Convertible Preferred Stock, par value $0.01 per share (the “Series K Convertible Preferred Stock”), convertible into 34 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 17 shares of common stock at an exercise price equal to $9.38 per share. The warrants expired three years from the issuance date. Of the $1,000,000 invested in the Private Placement, $572,044 was received in cash and $427,956 was from the conversion of outstanding indebtedness and interest. The Company incurred $43,334 of fees in conjunction with this private placement. The purchasers in the initial tranche of the private placement consisted of certain existing and new investors in the Company as well as all of the members of the Company’s Board of Directors. From the date of issuance of any shares of Series K Convertible Preferred Stock and until the earlier of the first anniversary of such date, the voluntary conversion of any shares of Series K Convertible Preferred Stock, or the date of any mandatory conversion (solely under the Company’s control based upon certain triggering events) of the Series K Convertible Preferred Stock, dividends will accrue on each share of Series K Convertible Preferred Stock at an annual rate of (i) four percent (4%) of the Purchase Price on those shares of Series K Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased from the Company shares of Series K Convertible Preferred Stock with an aggregate Purchase Price of less than $100,000, and (ii) six percent (6%) of the Purchase Price on those shares of Series K Convertible Preferred Stock purchased from the Company pursuant to the Securities Purchase Agreement by an individual purchaser who purchased shares of Series K Convertible Preferred Stock with an aggregate purchase price of at least $100,000. Dividends accruing on the Series K Convertible Preferred Stock shall accrue from day to day until the earlier of the first anniversary of the date of issuance of such shares of Series K Convertible Stock, the voluntary conversion of any shares of Series K Convertible Preferred Stock, or the date of any mandatory conversion of the Series K Convertible Preferred Stock, and shall be paid, as applicable, within fifteen (15) days of the first anniversary of the original issue date of the Series K Convertible Preferred Stock, within five (5) days of the voluntary conversion of shares of the Series K Convertible Preferred Stock, or within five (5) days of the mandatory conversion of shares of the Series K Convertible Preferred Stock. The Company may pay accrued dividends on the Series K Convertible Preferred Stock in cash or, in the sole discretion of the Board of Directors of the Company, in shares of its common stock in accordance with a specified formula. Each share of Series K Convertible Preferred Stock is convertible into 34 shares of common stock at the option of the holder on or after the six-month anniversary of the issuance of such share, subject to adjustment for stock splits, stock dividends, recapitalizations and similar transactions (the “Conversion Ratio”). Unless waived under certain circumstances by the holder of Series K Convertible Preferred Stock, such holder’s shares of Series K Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. At the election of the Company and upon required advance notice, each share of Series K Convertible Preferred Stock will automatically be converted into shares of common stock at the Conversion Ratio then in effect: (i) on or after the six-month anniversary of the original issuance date of the Series K Convertible Preferred Stock, the common stock trades on the OTCQB (or other primary trading market or exchange on which the common stock is then traded) at a price per share equal to at least $24.00 for 7 out of 10 consecutive trading days with average daily trading volume of at least 1,667 shares, (ii) on the first anniversary of the original issuance date of the Series K Convertible Preferred Stock or (iii) within three days of the completion of a firm-commitment underwritten registered public offering by the Company at a per share price equal to at least $24.00, with aggregate gross proceeds to the Company of not less than $2.5 million. Unless waived under certain circumstances by the holder of the Series K Convertible Preferred Stock, such holder’s Series K Convertible Preferred Stock may not be converted if upon such conversion the holder’s beneficial ownership would exceed certain thresholds. The proceeds from the sale of each Series K Unit were allocated between the Series K Convertible Preferred Stock and the Series K Warrants based on the relative fair value method. The estimated fair value of the Series K Warrants was determined using a Black-Scholes formula, resulting in an allocation of the gross proceeds of $271,422 to the total warrants issued. The allocation of the gross proceeds to the Series K Convertible Preferred Stock was $685,245, net of $43,334 in fees. In accordance with the provisions of ASC 470-20, an additional adjustment in the aggregate between Additional Paid in Capital and Accumulated Deficit of $1,495,415 was recorded for all tranches of Series K to reflect an implicit, deemed non-cash dividend related to the allocation of proceeds between the stock and warrants issued. The $1,495,415 represents the aggregate value of the adjustment to additional paid in capital related to the beneficial conversion feature of the Series K Convertible Preferred Stock. The value adjustment was calculated by subtracting the fair market value of the underlying common stock on the closing dates issuable upon conversion of the Series K Convertible Preferred Stock from the fair market value of the Series K Convertible Preferred Stock as determined when the Company performed a fair market value allocation of the proceeds to the Series K Convertible Preferred Stock and warrants. On January 29, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 4,875 units for a purchase price of $250.00 per unit or an aggregate Purchase Price of $1,218,750. This was the second tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the second tranche of the Private Placement consisted of certain existing and new investors in the Company, as well as all of the members of the Company’s board of directors. Each unit purchased in the second tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share, convertible into 34 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 17 shares of common stock at an exercise price equal to $9.38 per share, with a term that expired on January 29, 2017. On February 28, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 1,854 units for a purchase price of $340.00 per unit or an aggregate Purchase Price of $630,360. This was the third tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the third tranche of the Private Placement consisted of certain existing and new investors in the Company. Each unit purchased in the third tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share convertible into 34 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 17 shares of common stock at an exercise price equal to $12.75 per share, with a term that expired on February 28, 2017. On June 30, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 734 units for a purchase price of $300.00 per unit or an aggregate Purchase Price of $220,000. This was the fourth tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the fourth tranche of the Private Placement consisted of certain existing and new investors in the Company. Each unit purchased in the fourth tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share convertible into 34 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 17 shares of common stock at an exercise price equal to $11.25 per share, with a term that expired on June 30, 2017. On November 12, 2014, the Company entered into a Securities Purchase Agreement with various accredited investors, pursuant to which the Company sold an aggregate of 1,052 units for a purchase price of $250.00 per unit or an aggregate Purchase Price of $263,000. This was the fifth tranche of a $1.5 million private placement previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2013, which is incorporated by reference herein. The Purchasers in the fourth tranche of the Private Placement consisted of certain existing and new investors in the Company. Each unit purchased in the fifth tranche consists of (i) one share of Series K Convertible Preferred Stock, par value $0.01 per share convertible into 34 shares of the Company’s common stock, par value $0.01 per share and (ii) a warrant to purchase 17 shares of common stock at an exercise price equal to $9.38 per share, with a term that expired on November 12, 2017. The Private Placement was originally expected to raise $1.5 million and close on or before January 31, 2014. On January 29, 2014, the Company’s Board of Directors voted to increase the subscription amount of the Private Placement by $718,750. The Board of Directors also voted to extend the Private Placement until February 28, 2014. On February 28, 2014 the Company’s Board of Directors voted to increase the subscription amount once again to a total of $3.5 million and extended the closing to April 4, 2014. On April 13, 2014 the Company’s Board of Directors voted to increase the subscription amount by $1 million, to a total of $4.5 million, and extended the closing to May 31, 2014. On July 7, 2014 the Company’s Board of Directors voted to extend the closing to August 15, 2014. Together with the initial tranche of $1,000,000 that closed on December 12, 2013, the second tranche of $1,218,750 that closed January 29, 2014, the third tranche of $630,360 that closed February 28, 2014, the fourth tranche of $220,000 that closed June 30, 2014, and the fifth tranche of $263,000 that closed November 12, 2014,the total consideration received by the Company in the Private Placement is $3,332,110, which is comprised of $2,511,404 in cash and $820,706 from the conversion of outstanding indebtedness and Board of Director fees. The placement was closed after the November 12, 2014 round. On September 22, 2014 the Company issued 2,134 shares of common stock for the conversion of 64 shares of Series K Preferred Convertible Stock. In 2017, the Company returned 64 shares of Series K Preferred Convertible Stock as issued and outstanding. The conversion was done erroneously. The Company agreed to allow the recipient to keep the 2,134 shares of common st

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	(11) Subsequent Events During the three months ended March 31, 2018, we issued to Debenture holders 12,494 shares of common stock for quarterly interest of $52,371 issued in stock in lieu of cash. Of the 12,494 shares issued, 1,092 shares were issued to members of the Company’s Board of Directors, who are also Debenture holders. On various dates in March 2018, we received six-month, convertible loans of $150,000 from three accredited investors. The loans include a 10% original issue discount and are convertible into a qualified offering at the deal price. On March 14, 2018, we received a three month, non-convertible loan of $50,000 from a related party who was a member of the Company’s Board of Directors. On March 12, 2018, we received a six-month, convertible loan of $253,000 from an accredited investor. The loan has an original issue discount of $53,000. The loan can be converted at any time into common stock at a conversion price of $7.50. We agreed to issue the investor 6,750 shares of restricted common stock. On March 12, 2018, we received a six-month convertible loan of $85,000 from a privately-held investment firm. The Company paid total fees of $5,400 related to this loan. The Revolving Note was further amended on January 30, 2018 to increase the aggregate principal amount to $4,000,000 with all other terms unchanged. We received the additional $500,000 advances in January and March 2018. On February 22, 2018 we signed a Merchant Agreement with a lender. Under the agreement we received $110,000 in exchange for rights to all customer receipts until the lender is paid $147,400, which is collected at the rate of $921.25 per business day. The payments were secured by second position rights to all customer receipts until the loan has been paid in full. On February 12, 2018, we received a six-month, convertible loan of $100,000 from an accredited investor. The loan earns a one-time interest of 10%. $50,000 of the proceeds were used to pay off the outstanding balance of a previous loan from this lender. The loan can be converted at any time into common stock at a conversion price of $7.50. We issued the investor 5,000 shares of restricted common stock. On February 12, 2018, we issued 3,500 shares of restricted common stock to an accredited investor to extend the maturity date of our eight-month, non-convertible loan of $170,000 originated on March 21, 2017 to February 15, 2018. The accredited investor agreed to a further extension to March 31, 2018 in exchange for 3,500 shares of restricted common stock yet to be issued. On January 19, 2018, we received a six-month, convertible loan of $150,000 from an accredited investor. The loan earns a one-time interest of 10% and includes a 10% original issue discount. We also issued the investor 4,000 shares of restricted common stock. The loan can be converted at any time into common stock at a conversion price of $7.50. On January 16, 2018, we received a one year, convertible loan of $131,250 from an accredited investor. The loan earns interest of 4% per year. The loan can be converted into common stock after 180 calendar days at a discount of 40% to market price as defined in the loan. On January 3, 2018, we received a one year, convertible loan of $95,000 from an accredited investor. The loan includes a 5% original issue discount. The loan can be converted into common stock after 180 calendar days at a discount of 40% to market price as defined in the loan.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Principles of Consolidation	i. Principles of Consolidation The consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	ii. Use of Estimates To prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify impairment of assets, deferred tax assets, the costs associated with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded, beneficial conversion features and derivative liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.
Revenue Recognition	iii. Revenue Recognition Revenue is recognized when realized or when realizable and earned when all the following criteria have been met: persuasive evidence of an arrangement exists; goods were shipped, delivery of service has occurred and risk of loss has passed to the customer; the seller’s price to the buyer is fixed or determinable; and collectability is reasonably assured. Our current instruments, the Barocycler NEP3229 and NEP2320EXT, require a basic level of instrumentation expertise to set-up for initial operation. To support a favorable first experience for our customers, upon customer request and for an additional fee, we will send a highly trained technical representative to the customer site to install Barocyclers that we sell, lease, or rent through our domestic sales force. The installation process includes uncrating and setting up the instrument, followed by introductory user training. Product revenue related to current Barocycler instrumentation is recognized upon shipment of the unit, and in the case where the customer requests installation and training, the completion of the installation and introductory training process of the instrumentation at the customer location, for domestic installations. Product revenue related to sales of PCT instrumentation to our foreign distributors is recognized upon shipment through a common carrier. We provide for the expected costs of warranty upon the recognition of revenue for the sales of our instrumentation. Our sales arrangements do not provide our customers with a right of return. Product revenue related to the HUB440 and our consumable products such as PULSE Tubes, MicroTubes, and application specific kits is recorded upon shipment through a common carrier. Shipping costs are included in sales and marketing expense. Any shipping costs billed to customers are recognized as revenue. The Company applies ASC 845, “Accounting for Non-Monetary Transactions”, to account for products and services sold through non-cash transactions based on the fair values of the products and services involved, where such values can be determined. Non-cash exchanges would require revenue to be recognized at recorded cost or carrying value of the assets or services sold if any of the following conditions apply: a) The fair value of the asset or service involved is not determinable. b) The transaction is an exchange of a product or property held for sale in the ordinary course of business for a product or property to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. c) The transaction lacks commercial substance. The Company currently records revenue for its non-cash transactions at recorded cost or carrying value of the assets or services sold. We account for our lease agreements under the operating method. We record revenue over the life of the lease term and we record depreciation expense on a straight-line basis over the thirty-six month estimated useful life of the Barocycler instrument. The depreciation expense associated with assets under lease agreement is included in the “Cost of PCT products and services” line item in our consolidated statements of operations. Many of our lease and rental agreements allow the lessee to purchase the instrument at any point during the term of the agreement with partial or full credit for payments previously made. We pay all maintenance costs associated with the instrument during the term of the leases. Revenue from government grants is recorded when qualifying expenses are incurred under the grant in accordance with the terms of the grant award. Deferred revenue represents amounts received from grants and the Company’s service contracts for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying deliverables. Revenue from service contracts is recorded ratably over the length of the contract. Our transactions sometimes involve multiple elements (i.e., products and services). Revenue under multiple element arrangements is recognized in accordance with FASB ASC 605-25 Multiple-Element Arrangements (“ASC 605”)
Cash and Cash Equivalents	iv. Cash and Cash Equivalents Our policy is to invest available cash in short-term, investment grade interest-bearing obligations, including money market funds, and bank and corporate debt instruments. Securities purchased with initial maturities of three months or less are valued at cost plus accrued interest, which approximates fair value, and are classified as cash equivalents. Restricted cash is included in cash equivalents.
Research and Development	v. Research and Development Research and development costs, which are comprised of costs incurred in performing research and development activities including wages and associated employee benefits, facilities, consumable products and overhead costs that are expensed as incurred. In support of our research and development activities we utilize our Barocycler instruments that are capitalized as fixed assets and depreciated over their expected useful life.
Inventories	vi. Inventories Inventories are valued at the lower of cost (average cost) or net realizable value. The cost of Barocyclers consists of the cost charged by the contract manufacturer. The current year allowance was increased by a $159,600 inventory allowance for the older generation of Barocycler instruments held in stock, the NEP3229. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory as of December 31, is as follows: 2017 2016 Raw materials $ 288,295 $ 326,228 Finished goods 748,967 599,056 Inventory reserve (179,600 ) (20,000 ) Total $ 857,662 $ 905,284
Property and Equipment	vii. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. For financial reporting purposes, depreciation is recognized using the straight-line method, allocating the cost of the assets over their estimated useful lives of three years for certain laboratory equipment, from three to five years for management information systems and office equipment, and three years for all PCT finished units classified as fixed assets.
Intangible Assets	viii. Intangible Assets We have classified as intangible assets, costs associated with the fair value of acquired intellectual property. Intangible assets, including patents, are being amortized on a straight-line basis over nine years. We perform an annual review of our intangible assets for impairment. We capitalize any costs to renew or extend the term of our intangible assets. When impairment is indicated, any excess of carrying value over fair value is recorded as a loss. As of December 31, 2017 and 2016, the outstanding balance for intangible assets was $750,000 and $0, respectively.
Long-Lived Assets	ix. Long-Lived Assets The Company’s long-lived assets are reviewed for impairment in accordance with the guidance of the FASB ASC 360-10-05, Property, Plant, and Equipment
Concentrations	x. Concentrations Credit Risk Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions and university labs. Allowances are provided for estimated amounts of accounts receivable which may not be collected. At December 31, 2017, we determined that no allowance against accounts receivable was necessary and wrote off the prior year allowance of $28,169 as unrecoverable. The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: 2017 2016 Top Five Customers 37 % 29 % Federal Agencies 14 % 3 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2017 2016 Top Five Customers 85 % 82 % Federal Agencies 1 % 1 % Investment in Available-For-Sale Equity Securities As of December 31, 2017, we held 100,250 shares of common stock of Everest, a Polish publicly traded company listed on the Warsaw Stock Exchange. We exchanged 33,334 shares of our common stock for the 100,250 shares from Everest. We account for this investment in accordance with ASC 320 “Investments — Debt and Equity Securities”
Computation of Loss Per Share	xi. Computation of Loss per Share Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, warrants to acquire preferred stock convertible into common stock, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive. The following table illustrates our computation of loss per share for the years ended December 31: 2017 2016 Numerator: Net loss $ (10,715,561 ) $ (2,706,984 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 1,114,225 911,312 Loss per common share - basic and diluted $ (9.62 ) $ (2.97 ) The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: 2017 2016 Stock options 247,692 175,642 Convertible debt 947,203 891,132 Common stock warrants 899,542 881,990 Convertible preferred stock: Series D Convertible Preferred 25,000 25,000 Series G Convertible Preferred 26,857 28,857 Series H Convertible Preferred 33,334 33,334 Series H2 Convertible Preferred 70,000 70,000 Series J Convertible Preferred 115,267 117,367 Series K Convertible Preferred 229,334 227,200 2,594,229 2,450,522
Accounting for Income Taxes	xii. Accounting for Income Taxes We account for income taxes under the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. The Company considers many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to us for tax reporting purposes, and other relevant factors. A valuation allowance is established if it is more likely than not that all or a portion of the net deferred tax assets will not be realized. If substantial changes in the Company’s ownership should occur, as defined in Section 382 of the Internal Revenue Code, there could be significant limitations on the amount of net loss carry forwards that could be used to offset future taxable income. Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2017 and 2016, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2017 and 2016.
Accounting for Stock-Based Compensation	xiii. Accounting for Stock-Based Compensation We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize equity compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant. Employee awards are accounted for under ASC 718 where the awards are valued at grant date. Awards given to nonemployees are accounted for under ASC 505 where the awards are valued at earlier of commitment date or completion of services. Determining Fair Value of Stock Option Grants Valuation and Amortization Method Expected Term Compensation-Stock Compensation Expected Volatility Risk-Free Interest Rate Forfeitures Compensation-Stock Compensation The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2017: Assumptions Non-Employee Board Members CEO, other Officers and Employees Expected life 6.0 (yrs ) 6.0 (yrs ) Expected volatility 92.85%-104.83 % 105.71 % Risk-free interest rate 1.01%-1.53 % 1.63 % Forfeiture rate 5.00 % 5.00 % Expected dividend yield 0.0 % 0.0 % We recognized stock-based compensation expense of $406,427 and $379,964 for the years ended December 31, 2017 and 2016, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying consolidated statements of operations for the years ended December 31: 2017 2016 Research and development $ 92,055 $ 65,500 Selling and marketing 54,404 42,315 General and administrative 259,968 272,149 Total stock-based compensation expense $ 406,427 $ 379,964 During the years ended December 31, 2017 and 2016, the total fair value of stock options awarded was $487,964 and $0, respectively. As of December 31, 2017, total unrecognized compensation cost related to the unvested stock-based awards was $392,590, which is expected to be recognized over weighted average period of 1.66 years.
Advertising	xiv. Advertising Advertising costs are expensed as incurred. We incurred $5,899 in 2017 and $19,125 in 2016 for advertising.
Fair Value of Financial Instruments	xv. Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Short-term and long-term liabilities are primarily related to liabilities transferred under contractual arrangements with carrying values that approximate fair value.
Fair Value Measurements	xvi. Fair Value Measurements The Company follows the guidance of FASB ASC Topic 820, “ Fair Value Measurements and Disclosures ASC 820 The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are currently classified within Level 1 and that its financial liabilities are currently all classified within Level 3 in the fair value hierarchy. The Company changed its method of accounting for the Debentures and Warrants through the early adoption of ASU 2017-11 during the year ended December 31, 2017 on a modified retrospective basis. Accordingly, the Company reclassified the warrant derivative and conversion option derivative liabilities to additional paid in capital on its January 1, 2017 consolidated balance sheets totaling approximately $2.6 million, reduced debt discount by approximately $0.9 million and recorded the cumulative effect of the adoption to the beginning balance of accumulated deficit of approximately $2.5 million. Adoption of ASU 2017-11 The Company changed its method of accounting for the Debentures, Debenture Warrants and Series D Warrants through the early adoption of ASU 2017-11 during the year ended December 31, 2017 on a modified retrospective basis. Accordingly, the Company reclassified the warrant derivative and conversion option derivative liabilities to additional paid in capital on its January 1, 2017 consolidated balance sheets totaling approximately $2.6 million, reduced debt discount by approximately $0.9 million and recorded the cumulative effect of the adoption to the beginning balance of accumulated deficit of approximately $2.4 million. This resulted to an increase in stock warrants by $2.6 million and additional paid-in capital by $1.4 million. The following table provides a reconciliation of the warrant derivative liability, convertible debt, conversion option derivative liability, stock warrant, additional paid-in capital and accumulated deficit on the consolidated balance sheet as of December 31, 2016: Convertible debt, current portion Convertible debt, long term portion Warrant Derivative Liability Conversion Option Liability Warrants to acquire common stock Additional Paid-in Capital Accumulated deficit Balance, January 1, 2017 (Prior to adoption of ASU 2017-11) $ 4,005,702 $ 529,742 $ 1,685,108 $ 951,059 $ 6,325,102 $ 27,544,265 $ (42,264,190 ) Reclassified derivative liabilities and cumulative effect of adoption 769,316 154,152 $ (1,685,108 ) (951,059 ) 2,636,236 1,446,011 (2,369,548 ) Balance, January 1, 2017 (After adoption of ASU 2017-11) $ 4,775,018 $ 683,894 $ - $ - $ 8,961,338 $ 28,990,276 $ (44,633,738 ) The following tables set forth the Company’s financial assets and financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2017 and December 31, 2016. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. Fair value measurements at December 31, 2017 using: December 31, 2017 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 19,825 19,825 - - Total Financial Assets $ 19,825 $ 19,825 $ - $ - Fair value measurements at December 31, 2016 using: December 31, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 25,865 25,865 - - Total Financial Assets $ 25,865 $ 25,865 $ - $ - December 31, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 23,313 - - $ 23,313 Warrants Issued with Convertible Debt 1,661,795 - - 1,661,795 Conversion Option Derivative Liabilities 951,059 - - 951,059 Total Derivatives $ 2,636,167 $ - $ - $ 2,636,167 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: January 1, 2016 Issuance fair value Change in fair value December 31, 2016 Series D Preferred Stock Purchase Warrants $ 173,526 $ - $ (150,213 ) $ 23,313 Warrants Issued with Convertible Debt 3,122,450 1,094,432 (2,555,087 ) 1,661,795 Conversion Option Derivative Liabilities 3,940,791 1,547,127 (4,536,859 ) 951,059 Total Derivatives $ 7,236,767 $ 2,641,559 $ (7,242,159 ) $ 2,636,167 The issuance fair values for 2016 include the “day 1” derivative losses on the conversion option derivative liabilities of $1,337,510, which are included in “change in fair value of derivative liabilities” in the consolidated statements of operations. There were no derivative liabilities as of December 31, 2017. The fair value of the derivative liabilities was determined using a binomial pricing model. The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2016 Expected life (in months) 60.0 5.0 Expected volatility 104.5 % 83.5 % Risk-free interest rate 0.875 % 0.62 % Exercise price $ 24.30 $ 7.50 Fair value per warrant $ 16.20 $ 0.60 The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt in 2016 reflected on a per share common stock equivalent basis. Assumptions At Issuance Fair value Warrants revalued at December 31, 2016 Expected life (in months) 60.0 43.0-51.0 Expected volatility 118.3-120.1 % 110.0-116.0 % Risk-free interest rate 1.48-1.69 % 1.93 % Exercise price $ 12.00 $ 12.00 Fair value per warrant $ 5.70-$6.30 $ 3.60-4.20 The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value At Settlement fair value Conversion options revalued at December 31, 2016 Expected life (in months) 6.0-24.0 0-18.0 6.0-15.0 Expected volatility 104.2-153.8 % 86.9%-142.2 % 84.4-94.8 % Risk-free interest rate 0.05-0.99 % 0.01-0.72 % 0.62-0.85 % Exercise price $ 3.00-$10.50 $ 3.00-$7.50 $ 8.40 Fair value per conversion option $ 2.70-$8.40 $ 2.10-$7.80 $ 0.90-$1.80
Reclassifications	xvii. Reclassifications Certain prior year amounts have been reclassified to conform to our current year presentation.
Recently Issued Accounting Standards	xviii. Recently Issued Accounting Standards In November 2016, the Financial Accounting Standards Board (the FASB) issued Accounting Standards Update (ASU) No. 2016-18 (ASU 2016-18). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017. As early adoption of this amendment is permitted, the Company has adopted the update retrospectively to each period presented. The adoption of this guidance did not have a material impact on the company’s consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-09, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 became effective for the Company on January 1, 2017. The adoption of this guidance did not have a material impact on the Company’s consolidated Financial Statements. In February 2016, the FASB issued ASU 2016-02, which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated Financial Statements. In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) which amended the existing accounting standards for revenue recognition. ASU 2014-09 establishes principles for recognizing revenue upon the transfer of promised goods or services to customers, in an amount that reflects the expected consideration received in exchange for those goods or services. In July 2015, the FASB deferred the effective date for annual reporting periods beginning after December 15, 2017 (including interim reporting periods within those periods). The amendments may be applied retrospectively to each prior period (full retrospective) or retrospectively with the cumulative effect recognized as of the date of initial application (modified retrospective). The Company will adopt ASU 2014-09 in the first quarter of 2018 and apply the modified retrospective approach. The Company’s primary source of revenues is from instrument sales which are considered distinct performance obligations and are recognized upon shipment, the Company does not expect the impact on its consolidated financial statements to be material.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Inventories	The composition of inventory as of December 31, is as follows: 2017 2016 Raw materials $ 288,295 $ 326,228 Finished goods 748,967 599,056 Inventory reserve (179,600 ) (20,000 ) Total $ 857,662 $ 905,284
Summary of Customer Concentration Risk Percentage	The following table illustrates the level of concentration of the below two groups within revenue as a percentage of total revenues during the years ended December 31: 2017 2016 Top Five Customers 37 % 29 % Federal Agencies 14 % 3 % The following table illustrates the level of concentration of the below two groups within accounts receivable as a percentage of total accounts receivable balance as of December 31: 2017 2016 Top Five Customers 85 % 82 % Federal Agencies 1 % 1 %
Summary of Computation of Loss Per Share	The following table illustrates our computation of loss per share for the years ended December 31: 2017 2016 Numerator: Net loss $ (10,715,561 ) $ (2,706,984 ) Denominator for basic and diluted loss per share: Weighted average common shares outstanding 1,114,225 911,312 Loss per common share - basic and diluted $ (9.62 ) $ (2.97 )
Summary of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive for the years ended December 31: 2017 2016 Stock options 247,692 175,642 Convertible debt 947,203 891,132 Common stock warrants 899,542 881,990 Convertible preferred stock: Series D Convertible Preferred 25,000 25,000 Series G Convertible Preferred 26,857 28,857 Series H Convertible Preferred 33,334 33,334 Series H2 Convertible Preferred 70,000 70,000 Series J Convertible Preferred 115,267 117,367 Series K Convertible Preferred 229,334 227,200 2,594,229 2,450,522
Summary of Assumptions for Grants of Stock Options	The following table summarizes the assumptions we utilized for grants of stock options to the three sub-groups of our stock option recipients during the year ended December 31, 2017: Assumptions Non-Employee Board Members CEO, other Officers and Employees Expected life 6.0 (yrs ) 6.0 (yrs ) Expected volatility 92.85%-104.83 % 105.71 % Risk-free interest rate 1.01%-1.53 % 1.63 % Forfeiture rate 5.00 % 5.00 % Expected dividend yield 0.0 % 0.0 %
Summary of Stock Based Compensation Expense	The following table summarizes the effect of this stock-based compensation expense within each of the line items within our accompanying consolidated statements of operations for the years ended December 31: 2017 2016 Research and development $ 92,055 $ 65,500 Selling and marketing 54,404 42,315 General and administrative 259,968 272,149 Total stock-based compensation expense $ 406,427 $ 379,964
Schedule of Reconciliation Related to Liabilities	The following table provides a reconciliation of the warrant derivative liability, convertible debt, conversion option derivative liability, stock warrant, additional paid-in capital and accumulated deficit on the consolidated balance sheet as of December 31, 2016: Convertible debt, current portion Convertible debt, long term portion Warrant Derivative Liability Conversion Option Liability Warrants to acquire common stock Additional Paid-in Capital Accumulated deficit Balance, January 1, 2017 (Prior to adoption of ASU 2017-11) $ 4,005,702 $ 529,742 $ 1,685,108 $ 951,059 $ 6,325,102 $ 27,544,265 $ (42,264,190 ) Reclassified derivative liabilities and cumulative effect of adoption 769,316 154,152 $ (1,685,108 ) (951,059 ) 2,636,236 1,446,011 (2,369,548 ) Balance, January 1, 2017 (After adoption of ASU 2017-11) $ 4,775,018 $ 683,894 $ - $ - $ 8,961,338 $ 28,990,276 $ (44,633,738 )
Schedule of Liabilities Measured at Fair Value On Recurring Basis	The following tables set forth the Company’s financial assets and financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2017 and December 31, 2016. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s management. Fair value measurements at December 31, 2017 using: December 31, 2017 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 19,825 19,825 - - Total Financial Assets $ 19,825 $ 19,825 $ - $ - Fair value measurements at December 31, 2016 using: December 31, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Available-For-Sale Equity Securities 25,865 25,865 - - Total Financial Assets $ 25,865 $ 25,865 $ - $ - December 31, 2016 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Series D Preferred Stock Purchase Warrants $ 23,313 - - $ 23,313 Warrants Issued with Convertible Debt 1,661,795 - - 1,661,795 Conversion Option Derivative Liabilities 951,059 - - 951,059 Total Derivatives $ 2,636,167 $ - $ - $ 2,636,167 The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs: January 1, 2016 Issuance fair value Change in fair value December 31, 2016 Series D Preferred Stock Purchase Warrants $ 173,526 $ - $ (150,213 ) $ 23,313 Warrants Issued with Convertible Debt 3,122,450 1,094,432 (2,555,087 ) 1,661,795 Conversion Option Derivative Liabilities 3,940,791 1,547,127 (4,536,859 ) 951,059 Total Derivatives $ 7,236,767 $ 2,641,559 $ (7,242,159 ) $ 2,636,167
Schedule of Fair Value Assumptions	The fair value of the derivative liabilities was determined using a binomial pricing model. The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis. Assumptions November 10, 2011 Warrants revalued at December 31, 2016 Expected life (in months) 60.0 5.0 Expected volatility 104.5 % 83.5 % Risk-free interest rate 0.875 % 0.62 % Exercise price $ 24.30 $ 7.50 Fair value per warrant $ 16.20 $ 0.60 The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt in 2016 reflected on a per share common stock equivalent basis. Assumptions At Issuance Fair value Warrants revalued at December 31, 2016 Expected life (in months) 60.0 43.0-51.0 Expected volatility 118.3-120.1 % 110.0-116.0 % Risk-free interest rate 1.48-1.69 % 1.93 % Exercise price $ 12.00 $ 12.00 Fair value per warrant $ 5.70-$6.30 $ 3.60-4.20 The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis. Assumptions At Issuance fair value At Settlement fair value Conversion options revalued at December 31, 2016 Expected life (in months) 6.0-24.0 0-18.0 6.0-15.0 Expected volatility 104.2-153.8 % 86.9%-142.2 % 84.4-94.8 % Risk-free interest rate 0.05-0.99 % 0.01-0.72 % 0.62-0.85 % Exercise price $ 3.00-$10.50 $ 3.00-$7.50 $ 8.40 Fair value per conversion option $ 2.70-$8.40 $ 2.10-$7.80 $ 0.90-$1.80

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment as of December 31, 2017 and 2016 consisted of the following components: December 31, 2017 2016 Laboratory and manufacturing equipment $ 240,670 $ 226,326 Office equipment 173,312 165,832 Leasehold improvements 8,117 8,117 PCT collaboration, demonstration and leased systems 461,858 461,858 Total property and equipment 883,957 862,133 Less accumulated depreciation (861,295 ) (852,720 ) Net book value $ 22,662 $ 9,413

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets at December 31, 2017 and 2016 consisted of the following: December 31, 2017 2016 BaroFold Patents $ 750,000 $ - Less accumulated amortization - - Net book value $ 750,000 $ -

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Deferred Tax Liabilities	Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2017 and 2016 are as follows: 2017 2016 Long term deferred taxes: Inventories $ 49,067 $ 7,856 Accounts receivable allowance - 17,253 Other accruals 75,992 33,399 Accelerated tax depreciation 6,945 14,582 Non-cash, stock-based compensation, nonqualified 606,020 711,676 Impairment loss on investment 103,748 146,782 Goodwill and intangibles - - Operating loss carry forwards and tax credits 12,196,765 13,561,012 Less: valuation allowance (13,038,537 ) (14,492,560 ) Total net deferred tax assets $ - $ -
Schedule of Effective Income Tax (Benefit) Provision Rate	Our effective income tax (benefit) provision rate was different than the statutory federal income tax (benefit) provision rate as follows for the years ended December 31: 2017 2016 Federal tax provision rate 35 % 34 % Permanent differences (0 )% 24 % State tax expense 0 % 0 % Refundable AMT and R&D tax credit 0 % 0 % Net operating loss carry back 0 % 0 % Valuation allowance (35 )% (58 )% Effective income tax provision 0 % 0 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Rental Payments Required Under Operating Leases	Following is a schedule by years of future minimum rental payments required under operating leases with initial or remaining non-cancelable lease terms in excess of one year as of December 31, 2017: 2018 $ 166,353 2019 82,953 2020 82,953 Thereafter - Total minimum payments required $ 332,259

Convertible Debt and Other De25

Convertible Debt and Other Debt (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Convertible Debts and Outstanding Balances	The specific terms of the convertible notes and outstanding balances as of December 31, 2017 are listed in the tables below. Convertible Notes Inception Date Term Loan Amount Outstanding Balance Original Issue Discount Interest Rate Conversion Price(Convertible at Inception Date) Deferred Finance Fees Discount related to fair value of conversion feature and warrants/shares July 22, 2015 30 months 1 $ 2,180,000 $ 2,180,000 $ 218,000 2 10 % 3 $ 8.40 $ 388,532 $ 2,163,074 September 25, 2015 30 months 1 1,100,000 1,100,000 110,000 2 10 % 3 $ 8.40 185,956 1,022,052 October 2, 2015 30 months 1 150,000 150,000 15,000 2 10 % 3 $ 8.40 26,345 140,832 October 6, 2015 30 months 1 30,000 30,000 3,000 2 10 % 3 $ 8.40 5,168 26,721 October 14, 2015 30 months 1 50,000 50,000 5,000 2 10 % 3 $ 8.40 8,954 49,377 November 2, 2015 30 months 1 250,000 250,000 25,000 2 10 % 3 $ 8.40 43,079 222,723 November 10, 2015 30 months 1 50,000 50,000 5,000 2 10 % 3 $ 8.40 8,790 46,984 November 12, 2015 30 months 1 215,000 215,000 21,500 2 10 % 3 $ 8.40 38,518 212,399 November 20, 2015 30 months 1 200,000 200,000 20,000 2 10 % 3 $ 8.40 37,185 200,000 December 4, 2015 30 months 1 170,000 170,000 17,000 2 10 % 3 $ 8.40 37,352 170,000 December 11, 2015 30 months 1 360,000 360,000 36,000 2 10 % 3 $ 8.40 75,449 360,000 December 18, 2015 30 months 1 55,000 55,000 5,500 2 10 % 3 $ 8.40 11,714 55,000 December 31, 2015 30 months 1 100,000 100,000 10,000 2 10 % 3 $ 8.40 20,634 100,000 January 11, 2016 30 months 1 100,000 100,000 10,000 2 10 % 3 $ 8.40 24,966 80,034 January 20, 2016 30 months 1 50,000 50,000 5,000 2 10 % 3 $ 8.40 9,812 40,188 January 29, 2016 30 months 1 300,000 300,000 30,000 2 10 % 3 $ 8.40 60,887 239,113 February 26, 2016 30 months 1 200,000 200,000 20,000 2 10 % 3 $ 8.40 43,952 156,048 March 10, 2016 30 months 1 125,000 125,000 12,500 2 10 % 3 $ 8.40 18,260 106,740 March 18, 2016 30 months 1 360,000 360,000 36,000 2 10 % 3 $ 8.40 94,992 265,008 March 24, 2016 30 months 1 106,667 106,667 10,667 2 10 % 3 $ 8.40 15,427 91,240 March 31, 2016 30 months 1 177,882 177,882 17,788 2 10 % 3 $ 8.40 2,436 175,446 June 15, 2016 6 months 40,000 - - 12 % $ 13.50 - 3,680 June 17, 2016 6 months 40,000 - - 12 % $ 13.50 - 3,899 June 22, 2016 6 months 35,000 - - 12 % $ 13.50 - 3,373 July 6, 2016 6 months 85,000 - - 12 % $ 13.50 - 15,048 July 29, 2016 6 months 100,000 - - 12 % $ 13.50 - 25,518 September 15, 2016 8 months 500,000 - 85,541 9 % $ 13.50 - 65,972 October 11, 2017 12 months 85,000 - - 5 % - 4,250 - October 20, 2017(4) 12 months 150,000 150,000 - 5 % $ 7.50 7,500 - October 25, 2017 6 months 103,000 103,000 - 12 % - 3,000 October 27, 2017 12 months 170,000 170,000 - 5 % - 4,250 10,000 November 13, 2017 9 months 380,000 380,000 15,200 8 % $ 7.50 15,200 46,274 November 22, 2017 12 months 100,000 100,000 10,000 5 % - 2,000 - November 28, 2017 10 months 103,000 103,000 3,000 12 % - - - November 29, 2017 6 months 150,000 150,000 - 15 % $ 7.50 - 15,200 November 30, 2017 3 months 50,000 50,000 8 % $ 7.50 December 5, 2017 3 months 52,500 52,500 - 10 % $ 7.50 2,500 - December 6, 2017 4 months 100,000 100,000 - 10 % $ 7.50 - - December 11, 2017 6 months 130,000 130,000 1,500 5 % - 6,500 6,460 December 19, 2017 6 months 110,000 110,000 1,500 5 % - 5,500 5,775 December 28, 2017 6 months 55,000 55,000 - 15 % $ 7.50 5,000 - December 29, 2017 12 months 105,000 105,000 - 5 % - 5,000 - $ 8,973,049 $ 8,088,049 $ 749,696 $ 1,219,108 $ 6,124,178 1) The loan term was extended by 180 days and further extended on January 15, 2018 by 60 days to repay in common stock. The July 22, 2015 Debentures of $2,180,000 is currently past due as of March 19, 2018. 2. The original issue discount is reflected in the first year. 3. The annual interest started accruing in the second year. 4. On October 20, 2017, Company issued to EMA Financial, LLC a 5% one year convertible note in the amount of $150,000, less $7,500 from OID and fees. The note is convertible at $7.50 per share, provided however, if the Company fails to comply with Section 1.9 of the note then the conversion price shall be 65% of the lowest sale price for the Common Stock on the Principal Market during the twenty (20) consecutive Trading Days immediately preceding the Conversion Date or the closing bid price, whichever is lower.
Summary of Changes in Convertible Debt, Net of Unamortized Discounts	The following table provides a summary of the changes in convertible debt and revolving note payable, net of unamortized discounts, during 2017: 2017 Balance at January 1, $ 5,273,937 Adjustment due to ASU 2017-11 923,468 Issuance of convertible debt, face value 4,093,500 Deferred financing cost (267,650 ) Debt discount related to one-time interest charge (225,000 ) Debt discount from incentive shares to increase the Revolving Note aggregate principal limit (150,000 ) Debt discount from shares and warrants issued with the notes (750,705 ) Payments (925,541 ) Accretion of interest and amortization of debt discount to interest expense through December 31, 3,815,767 Balance at December 31, 11,787,776 Less: current portion 11,787,776 Convertible debt, long-term portion $ -
Schedule of Merchant Agreements	The following table shows our Merchant Agreements as of December 31, 2017. Inception Date Purchase Price Purchased Amount Outstanding Balance Daily Payment Interest Rate Deferred Finance Fees Note January 6, 2016 250,000 322,500 $ - 1,279.76 14 % 2,500 1 February 8, 2016 100,000 129,900 - 927.00 15 % 2,000 August 16, 2016 70,000 90,930 - 650.00 15 % 1,590 August 26, 2016 125,000 166,250 - 1,386.00 6 % 2,535 February 6, 2017 125,000 161,250 - 1,343.75 15 % 1,250 March 2, 2017 75,750 97,718 - 775.74 7 % 750 June 6, 2017 250,000 330,000 - 1,833.00 5 % 6,250 June 21, 2017 150,000 190,500 - 1,361.00 15 % 1,498 July 17, 2017 125,000 160,000 - 1,250.00 7 % 1,250 September 29, 2017 75,000 102,000 (1,200 ) 1,200.00 15 % 1,500 October 25, 2017 110,000 153,890 71,233 1,539.00 15 % 8,800 December 7, 2017 160,000 212,800 157,088 1,251.76 25 % 5,799 December 12, 2017 160,000 212,800 159,186 1,251.76 15 % 5,258 $ 1,775,750 $ 2,330,538 $ 386,307 $ 40,980 1) The Company recognized a gain in fiscal year 2016 on the settlement of the previous loan of $5,044 which was credited to interest expense.

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Schedule of Assumption Used	In connection with the Series K Warrants, we calculated the fair value of the warrants received as described above using the Black- Scholes formula with the below assumptions: Assumptions Series K Warrants December 12, 2013 Series K Warrants January 29, 2014 Series K Warrants February 28, 2014 Series K Warrants June 30, 2014 Series K Warrants November 12, 2014 Contractual life (in months) 36 36 36 36 36 Expected volatility 136.1 152.4 152.7 153.9 153.9 Risk-free interest rate 0.39 % 0.39 % 0.39 % 0.90 % 0.90 % Exercise price $ 9.38 $ 9.38 $ 12.75 $ 11.25 $ 9.38 Fair value per warrant $ 6.00 $ 9.00 $ 11.10 $ 8.70 $ 6.90
Schedule of Concerning Options and Warrants Outstanding and Exercisable	The following tables summarize information concerning options and warrants outstanding and exercisable: Stock Options Warrants Total Shares Weighted Average price per share Shares Weighted Average price per share Shares Exercisable Balance outstanding, January 1, 2016 185,708 $ 13.20 974,256 $ 13.20 1,159,964 1,055,483 Granted - - 272,652 12.60 272,652 Exercised - - (2,334 ) 9.30 (2,334 ) Expired (6,200 ) 30.00 (362,585 ) 16.50 (368,785 ) Forfeited (3,866 ) 15.30 - - (3,866 ) Balance outstanding, December 31, 2016 175,642 $ 12.60 881,989 $ 12.00 1,057,631 991,032 Granted 87,198 8.40 245,661 11.14 332,859 Exercised - - (19,889 ) 7.50 (19,889 ) Expired (3,202 ) 30.00 (208,219 ) 11.46 (211,421 ) Forfeited (11,946 ) 9.82 - - (11,946 ) Balance outstanding, December 31, 2017 247,692 $ 10.95 899,542 $ 12.03 1,147,234 1,073,850
Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range	Options Outstanding Options Exercisable Weighted Average Weighted Average Range of Exercise Prices Number of Options Remaining Contractual Life (Years) Exercise Price Number of Options Remaining Contractual Life (Years) Exercise Price $ 7.50 - $11.99 133,580 8.3 $ 8.63 80,997 7.7 $ 8.78 12.00 – 14.99 88,705 7.7 12.00 67,904 7.6 12.00 15.00 – 17.99 7,547 4.6 15.00 7,547 4.6 15.00 18.00 – 20.99 12,854 2.1 18.00 12,854 2.1 18.00 21.00 – 30.00 5,006 2.7 30.00 5,006 2.7 30.00 $ 7.50 - $30.00 247,692 7.5 $ 10.95 174,308 7.0 $ 11.59

Business Overview (Details Narr

Business Overview (Details Narrative) - lb	Jun. 05, 2017	Dec. 31, 2017
Pounds per square inch		35,000
Reverse stock split	1-for-30 reverse stock split
PBI Europe [Member]
Percentage of ownership interest		49.00%
Percentage of investment bank retaining		51.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net proceeds from additional convertible and non-convertible debt	$ 6,700,000
Cash and cash equivalents	$ 81,033	$ 138,363	$ 116,783

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Intangible assets amortization of straight line period	9 years
Inventory allowance	$ 159,600
Intangible assets	750,000	$ 0
Allowance for doubtful accounts receibale write offs	28,169
Impairment loss on investment	6,069	373,682
Realized losses	$ 6,069
Forfeiture rate	5.00%
Stock-based compensation expense	$ 406,427	379,964
Fair value of stock options awarded	487,964	0
Fair value of unvested stock options amortized	$ 392,590
Share-based compensation, nonvested awards, compensation cost not yet recognized weighted average period	1 year 7 months 28 days
Advertising costs	$ 5,899	19,125
Warrant and option derivative to additional paid in capital	2,600,000
Reduced debt discount	900,000
Cumulative accumulated deficit	2,400,000
Increase in stock warrant	2,600,000
Additional paid in capital	$ 1,400,000	(79,035)
Derivative liabilities		$ 1,337,510
Everest[Member]
Sale of stock number of shares received	100,250
Number of common stock shares exchanged during the period	33,334
Laboratory Equipment [Member]
Property and equipment estimated useful life	3 years
Management Information Systems And Office Equipment [Member] | Minimum [Member]
Property and equipment estimated useful life	3 years
Management Information Systems And Office Equipment [Member] | Maximum [Member]
Property and equipment estimated useful life	5 years
PCT Finished Units Classified As Fixed Assets [Member]
Property and equipment estimated useful life	3 years
Everest Investments Holdings S.A. [Member]
Sale of stock number of shares received	100,250
Fair value of investment	$ 19,825
Shares closing price per share	$ 0.1978

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Raw materials	$ 288,295	$ 326,228
Finished goods	748,967	599,056
Inventory reserve	(179,600)	(20,000)
Total	$ 857,662	$ 905,284

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Summary of Customer Concentration Risk Percentage (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Top Five Customers [Member] | Revenue [Member]
Concentration as a percentage	37.00%	29.00%
Top Five Customers [Member] | Accounts Receivable [Member]
Concentration as a percentage	85.00%	82.00%
Federal Agencies [Member] | Revenue [Member]
Concentration as a percentage	14.00%	3.00%
Federal Agencies [Member] | Accounts Receivable [Member]
Concentration as a percentage	1.00%	1.00%

Summary of Significant Accoun32

Summary of Significant Accounting Policies - Summary of Computation of Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Net loss	$ (10,715,561)	$ (2,706,984)
Weighted average common shares outstanding	1,114,225	911,312
Loss per common share - basic and diluted	$ (9.62)	$ (2.97)

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Summary of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Stock Options [Member]
Total potentially dilutive shares	247,692	175,642
Convertible Debt [Member]
Total potentially dilutive shares	947,203	891,132
Common Stock Warrants [Member]
Total potentially dilutive shares	899,542	881,990
Series D Convertible Preferred Stock [Member]
Total potentially dilutive shares	25,000	25,000
Series G Convertible Preferred Stock [Member]
Total potentially dilutive shares	26,857	28,857
Series H Convertible Preferred Stock [Member]
Total potentially dilutive shares	33,334	33,334
Series H2 Convertible Preferred Stock [Member]
Total potentially dilutive shares	70,000	70,000
Series J Convertible Preferred Stock [Member]
Total potentially dilutive shares	115,267	117,367
Series K Convertible Preferred Stock [Member]
Total potentially dilutive shares	229,334	227,200
Potentially Dilutive Shares [Member]
Total potentially dilutive shares	2,594,229	2,450,522

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Summary of Assumptions for Grants of Stock Options (Details)	12 Months Ended
	Dec. 31, 2017
Non-Employee Board Members [Member]
Expected life	6 years
Expected volatility Minimum	92.85%
Expected volatility Maximum	104.83%
Risk-free interest rate Minimum	1.01%
Risk-free interest rate Maximum	1.53%
Forfeiture rate	5.00%
Expected dividend yield	0.00%
CEO, other Officers and Employees [Member]
Expected life	6 years
Expected volatility Maximum	105.71%
Risk-free interest rate Maximum	1.63%
Forfeiture rate	5.00%
Expected dividend yield	0.00%

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Summary of Stock Based Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Total stock-based compensation expense	$ 406,427	$ 379,964
Research and Development [Member]
Total stock-based compensation expense	92,055	65,500
Selling and Marketing [Member]
Total stock-based compensation expense	54,404	42,315
General and Administrative [Member]
Total stock-based compensation expense	$ 259,968	$ 272,149

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Schedule of Reconciliation Related to Liabilities (Details)	12 Months Ended
	Dec. 31, 2017USD ($)
Convertible Debt, Current Portion [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	$ 4,005,702
Reclassified derivative liabilities and cumulative effect of adoption	769,316
Balance, January 1, 2017 (After adoption of ASU 2017-11)	4,775,018
Convertible Debt, Long Term Portion [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	529,742
Reclassified derivative liabilities and cumulative effect of adoption	154,152
Balance, January 1, 2017 (After adoption of ASU 2017-11)	683,894
Warrant Derivative Liability [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	1,685,108
Reclassified derivative liabilities and cumulative effect of adoption	(1,685,108)
Balance, January 1, 2017 (After adoption of ASU 2017-11)
Conversion Option Liability [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	951,059
Reclassified derivative liabilities and cumulative effect of adoption	(951,059)
Balance, January 1, 2017 (After adoption of ASU 2017-11)
Warrants to Acquire Common Stock [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	6,325,102
Reclassified derivative liabilities and cumulative effect of adoption	2,636,236
Balance, January 1, 2017 (After adoption of ASU 2017-11)	8,961,338
Additional Paid-in Capital [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	27,544,265
Reclassified derivative liabilities and cumulative effect of adoption	1,446,011
Balance, January 1, 2017 (After adoption of ASU 2017-11)	28,990,276
Accumulated Deficit [Member]
Balance, January 1, 2017 (Prior to adoption of ASU 2017-11)	(42,264,190)
Reclassified derivative liabilities and cumulative effect of adoption	(2,369,548)
Balance, January 1, 2017 (After adoption of ASU 2017-11)	$ (44,633,738)

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Schedule of Liabilities Measured at Fair Value On Recurring Basis (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
Total Financial Assets	$ 25,865	$ 19,825
Fair value of derivative liability	2,636,167
Balance	7,236,767
Issuance fair value	2,641,559
Change in Fair Value	(7,242,159)
Balance	2,636,167
Quoted Prices in Active Markets (Level 1) [Member]
Total Financial Assets	25,865	19,825
Fair value of derivative liability
Significant Other Observable Inputs (Level 2) [Member]
Total Financial Assets
Fair value of derivative liability
Significant Unobservable Inputs (Level 3) [Member]
Total Financial Assets
Fair value of derivative liability	2,636,167
Available-For-Sale Equity Securities [Member]
Total Financial Assets	25,865	19,825
Available-For-Sale Equity Securities [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Total Financial Assets	25,865	19,825
Available-For-Sale Equity Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Total Financial Assets
Available-For-Sale Equity Securities [Member] | Significant Unobservable Inputs (Level 3) [Member]
Total Financial Assets
Series D Preferred Stock Purchase Warrants [Member]
Fair value of derivative liability	23,313
Balance	173,526
Issuance fair value
Change in Fair Value	(150,213)
Balance	23,313
Series D Preferred Stock Purchase Warrants [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair value of derivative liability
Series D Preferred Stock Purchase Warrants [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair value of derivative liability
Series D Preferred Stock Purchase Warrants [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair value of derivative liability	23,313
Warrants Issued with Convertible Debt [Member]
Fair value of derivative liability	1,661,795
Balance	3,122,450
Issuance fair value	1,094,432
Change in Fair Value	(2,555,087)
Balance	1,661,795
Warrants Issued with Convertible Debt [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair value of derivative liability
Warrants Issued with Convertible Debt [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair value of derivative liability
Warrants Issued with Convertible Debt [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair value of derivative liability	1,661,795
Conversion Option Derivative Liabilities [Member]
Fair value of derivative liability	951,059
Balance	3,940,791
Issuance fair value	1,547,127
Change in Fair Value	(4,536,859)
Balance	951,059
Conversion Option Derivative Liabilities [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair value of derivative liability
Conversion Option Derivative Liabilities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair value of derivative liability
Conversion Option Derivative Liabilities [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair value of derivative liability	$ 951,059

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Schedule of Fair Value Assumptions (Details) - $ / shares	Nov. 10, 2011	Dec. 31, 2016
Expected life (in months)	60 months
Expected volatility	104.50%
Risk-free interest rate	0.875%
Exercise price	$ 24.30
Fair value per share	$ 16.20
Warrants Revalued at December 31, 2016 [Member]
Expected life (in months)		5 months
Expected volatility		83.50%
Risk-free interest rate		0.62%
Exercise price		$ 7.50
Fair value per share		$ 0.60
Warrants Revalued at December 31, 2016 [Member] | Warrants Issued with Convertible Debt [Member]
Risk-free interest rate		1.93%
Exercise price		$ 12
Warrants Revalued at December 31, 2016 [Member] | Warrants Issued with Convertible Debt [Member] | Minimum [Member]
Expected life (in months)		43 months
Expected volatility		110.00%
Fair value per share		$ 3.60
Warrants Revalued at December 31, 2016 [Member] | Warrants Issued with Convertible Debt [Member] | Maximum [Member]
Expected life (in months)		51 months
Expected volatility		116.00%
Fair value per share		$ 4.20
Issuance Fair Value [Member] | Minimum [Member]
Expected life (in months)		6 months
Expected volatility		104.20%
Risk-free interest rate		0.05%
Exercise price		$ 3
Fair value per share		$ 2.70
Issuance Fair Value [Member] | Maximum [Member]
Expected life (in months)		24 months
Expected volatility		153.80%
Risk-free interest rate		0.99%
Exercise price		$ 10.50
Fair value per share		$ 8.40
Issuance Fair Value [Member] | Warrants Issued with Convertible Debt [Member]
Expected life (in months)		60 months
Exercise price		$ 12
Issuance Fair Value [Member] | Warrants Issued with Convertible Debt [Member] | Minimum [Member]
Expected volatility		118.30%
Risk-free interest rate		1.48%
Fair value per share		$ 5.70
Issuance Fair Value [Member] | Warrants Issued with Convertible Debt [Member] | Maximum [Member]
Expected volatility		120.10%
Risk-free interest rate		1.69%
Fair value per share		$ 6.30
At Settlement Fair Value [Member] | Minimum [Member]
Expected life (in months)		0 months
Expected volatility		86.90%
Risk-free interest rate		0.01%
Exercise price		$ 3
Fair value per share		$ 2.10
At Settlement Fair Value [Member] | Maximum [Member]
Expected life (in months)		18 months
Expected volatility		142.20%
Risk-free interest rate		0.72%
Exercise price		$ 7.50
Fair value per share		7.80
Conversion Options Revalued at December 31, 2016 [Member]
Exercise price		$ 8.40
Conversion Options Revalued at December 31, 2016 [Member] | Minimum [Member]
Expected life (in months)		6 months
Expected volatility		84.40%
Risk-free interest rate		0.62%
Fair value per share		$ 0.90
Conversion Options Revalued at December 31, 2016 [Member] | Maximum [Member]
Expected life (in months)		15 months
Expected volatility		94.80%
Risk-free interest rate		0.85%
Fair value per share		$ 1.80

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 8,576	$ 17,939

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Laboratory and manufacturing equipment	$ 240,670	$ 226,326
Office equipment	173,312	165,832
Leasehold improvements	8,117	8,117
PCT collaboration, demonstration and leased systems	461,858	461,858
Total property and equipment	883,957	862,133
Less accumulated depreciation	(861,295)	(852,720)
Net book value	$ 22,662	$ 9,413

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Intangible assets amortization of straight line period	9 years
Amortization expense	$ 0	$ 0
Amortization expense, year one	80,000
Amortization expense, year two	80,000
Amortization expense, year three	80,000
Amortization expense, year four	80,000
Amortization expense, year five	80,000
BaroFold Patents [Member]
Amortization expense	$ 80,000

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
BaroFold Patents	$ 750,000
Less accumulated amortization
Net book value	$ 750,000

Retirement Plan (Details Narrat

Retirement Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Retirement Benefits [Abstract]
Company-matching contributions	$ 13,587	$ 22,627

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Dec. 22, 2017	Dec. 31, 2017	Dec. 31, 2016
Corporate tax rate		0.00%	0.00%
Research and development tax credit carryforwards		$ 6,945	$ 14,582
U.S. Tax Cuts and Jobs Act [Member]
Income tax description	Revised the U.S. corporate income tax regime by, among other things, lowering the U.S. corporate tax rate from 35% to 21% effective January 1, 2018. Under ASC 740, the tax effects of changes in tax laws must be recognized in the period in which the law was enacted.
Corporate tax rate	21.00%
Reduction in deferred tax assets and liabilities	$ 5,843,000
Federal Income Tax [Member]
Operating loss carry-forwards		$ 38,690,000
Operating loss carry-forwards expire term		2018 through 2038
Federal alternative minimum tax credit carryforwards for federal income tax		$ 217,000
Federal Income Tax [Member] | Research and Development Tax Credit Carryforward [Member]
Operating loss carry-forwards expire term		2018 through 2038
Research and development tax credit carryforwards		$ 1,089,000
State Income Tax [Member]
Operating loss carry-forwards		$ 31,735,000
Operating loss carry-forwards expire term		2030 through 2038
State Income Tax [Member] | Research and Development Tax Credit Carryforward [Member]
Operating loss carry-forwards expire term		2023 through 2033
Research and development tax credit carryforwards		$ 232,000

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Long term deferred taxes, Inventories	$ 49,067	$ 7,856
Long term deferred taxes, Accounts receivable allowance		17,253
Long term deferred taxes, Other accruals	75,992	33,399
Long term deferred taxes, Accelerated tax depreciation	6,945	14,582
Long term deferred taxes, Non-cash, stock-based compensation, nonqualified	606,020	711,676
Long term deferred taxes, Impairment loss on investment	103,748	146,782
Long term deferred taxes, Goodwill and intangibles
Long term deferred taxes, Operating loss carry forwards and tax credits	12,196,765	13,561,012
Long term deferred taxes, Less: valuation allowance	(13,038,537)	(14,492,560)
Long term deferred taxes, Total net deferred tax assets

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax (Benefit) Provision Rate (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Federal tax provision rate	35.00%	34.00%
Permanent differences	(0.00%)	24.00%
State tax expense	0.00%	0.00%
Refundable AMT and R&D tax credit	0.00%	0.00%
Net operating loss carry back	0.00%	0.00%
Valuation allowance	(35.00%)	(58.00%)
Effective income tax provision	0.00%	0.00%

Commitments and Contingencies47

Commitments and Contingencies (Details Narrative) - USD ($)	Dec. 29, 2017	Apr. 30, 2012	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Rental expenses			$ 6,913
Lease expire date			Dec. 30, 2020
Lease expiration term			The lease shall be automatically extended for additional three years unless either party terminates at least six months prior to the expiration of the current lease term.
BioMolecular Assays, Inc [Member]
Percentage of royalty on sales of products			5.00%
Royalties				$ 6,963
Percentage of royalty equal of license or other fees and royalties			20.00%
Battelle Memorial Institute [Member]
Minimum annual royalty			$ 4,000	3,000	$ 2,000	$ 1,200
Battelle Memorial Institute [Member] | 2018 [Member]
Minimum annual royalty			5,000
Target Discovery Inc [Member]
Minimum annual royalty			$ 30,000	$ 20,000
Monthly fees		$ 1,400
Payment for technical support service per day		$ 2,000
Corporate Office [Member]
Rental expenses	$ 6,950
Lease expire date	Dec. 31, 2018

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Rental Payments Required Under Operating Leases (Details)	Dec. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 166,353
2,019	82,953
2,020	82,953
Thereafter
Total minimum payments required	$ 332,259

Convertible Debt and Other De49

Convertible Debt and Other Debt (Details Narrative) - USD ($)	Dec. 12, 2017	Sep. 20, 2017	Sep. 12, 2017	Aug. 01, 2017	Jul. 25, 2017	May 19, 2017	May 02, 2017	Apr. 19, 2017	Mar. 21, 2017	Mar. 14, 2017	Feb. 15, 2017	Oct. 28, 2016	Sep. 15, 2016	Aug. 25, 2016	Aug. 16, 2016	Jul. 29, 2016	Jul. 02, 2016	Jun. 14, 2016	May 24, 2016	May 13, 2016	Feb. 08, 2016	Jul. 22, 2015	Jun. 30, 2016	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2017	Aug. 18, 2017	May 09, 2016	Jan. 20, 2016
Debt principal amount																						$ 2,180,000		$ 4,093,500	$ 4,093,500
Percentage of annual interest rates			10.00%
Debt conversion price per share																								$ 7.50	$ 7.50
Debt conversion into common stock shares																									61,307
Debt conversion amount																										$ 117,837
Gain on extinguishment of debt																									$ 185,452	5,044
Warrants rights description																									Subject to the terms and conditions of the Warrants, at any time commencing six months from the Final Closing, the Company has the right to call the Warrants for cancellation if the volume weighted average price of its Common Stock on the OTCQB (or other primary trading market or exchange on which the Common Stock is then traded) equals or exceeds three times the per share exercise price of the Warrants for 15 out of 20 consecutive trading days.
Amortized of debt discount																									$ 3,740,746
Fair value of warrant																									2,847,624
Original issue of discount			$ 25,000																					$ 0	0	740,628
Proceeds from common stock																										530,965
Gross proceeds from warrants																									186,802
Proceeds from convertible notes																								1,755,850	1,755,850	2,105,420
Proceeds from revolving note payable																									2,070,000	1,133,500
Number of shares issued			3,333
Shares issued during period, value																										610,000
Debt fee amount																								40,980	40,980
Proceeds from loan			$ 225,000
Unamortized debt discount			$ 25,000																					401,856	401,856	2,235,839
Repayment of debt																									925,541	107,000
Loan paid back date																						Mar. 19, 2018
Number of restricted stock issued during period	150,000	4,000
Original issue of discount percentage			35.00%
Convertible debt																								$ 0	$ 0
Minimum [Member]
Percentage of annual interest rates																								5.00%	5.00%
Convertible debentures term																								3 months
Maximum [Member]
Percentage of annual interest rates																								12.00%	12.00%
Convertible debentures term																								12 months
Other Convertible Notes [Member]
Debt principal amount																	$ 200,000
Percentage of annual interest rates													9.00%
Debt conversion price per share													$ 13.50			$ 13.50	$ 13.50		$ 13.50
Debt conversion into common stock shares													6,666			1,084	2,167	1,023
Issuance of warrants to purchase of common stock shares																	1,144		1,667
Warrant exercise price per share																			$ 16.50
Amortized of debt discount													$ 45,000			$ 25,518	$ 26,000
Fair value of warrant																			$ 12,406
Additional convertible debentures													500,000			100,000		$ 115,000	107,000
Beneficial conversion feature																12,759			$ 7,962
Proceeds from pay off outstanding balance of previous loan																	$ 85,000
Fair value of convertible note													434,028			$ 87,241
Original issue of discount													40,541
Proceeds from common stock													$ 65,972
Revolving Note [Member]
Debt principal amount																												$ 3,500,000
Issuance of warrants to purchase of common stock shares							16,667
Warrant exercise price per share							$ 12
Fair value of warrant																									$ 291,667
Fees and commission																									296,500
One-time interest amount																									350,000
Revolving Note [Member] | Investor [Member]
Amortized of debt discount																									$ 1,148,275
Revolving Note [Member] | Prior to April 28, 2017 [Member]
Percentage of annual interest rates																								10.00%	10.00%
Revolving Note [Member] | July 28, 2017 And October 28, 2017 [Member]
Percentage of annual interest rates																								4.00%	4.00%
Revolving Note [Member] | April 28, 2017 And July 28, 2017 [Member]
Percentage of annual interest rates																								4.00%	4.00%
Non-Convertible Loan [Member]
Percentage of annual interest rates								10.00%	10.00%	10.00%
Amortized of debt discount								$ 43,687		$ 46,748															$ 76,748
Number of shares issued								8,333
Proceeds from loan								$ 250,000		$ 250,000
Original issue of discount percentage								10.00%	10.00%	10.00%																	35.00%
Number of shares issued								833
Non-Convertible Loan [Member] | Investor [Member]
Debt conversion into common stock shares																									9,500
Amortized of debt discount									$ 35,079																$ 44,841
Unamortized debt discount																								$ 7,238	$ 7,238
Number of restricted stock issued during period									5,667	8,333
Original issue of discount percentage																								35.00%	35.00%
Convertible debt																								$ 170,000	$ 170,000
Non-Convertible Loan [Member] | Accredited Investor [Member]
Proceeds from loan									$ 170,000
90 Month Non Convertible Loan [Member]
Amortized of debt discount																									15,311
Unamortized debt discount																								$ 22,689	$ 22,689
Original issue of discount percentage																								35.00%	35.00%
Related Party Notes [Member]
Due to related parties																										20,000
Individuals [Member] | Other Notes [Member]
Amount borrowed																														$ 50,000
Lender [Member] | Other Convertible Notes [Member]
Debt conversion into common stock shares																				14,028
Debt conversion amount																				$ 117,837
Other note outstanding balance																								$ 0	$ 0
Board Of Directors [Member] | Convertible Debentures [Member]
Convertible debentures issued to related parties																								291,000	291,000
Placement Agent [Member] | Other Convertible Notes [Member]
Debt principal amount																								433,228	433,228
Amortized of debt discount																									1,955,193
Fair value of warrant																									2,101,786
Deferred finance fees																									621,500
Gross proceeds from warrants																									536,908
Investor [Member] | Revolving Note [Member]
Percentage of debt original issue discount on purchase price												40.00%
Issuance of warrants to purchase of common stock shares												20,834
Warrant exercise price per share							$ 12					$ 12
Fair value of convertible note												$ 2,000,000
Advance pursuant to revolving note												$ 3,500,000
Number of shares issued							16,667
Shares issued during period, value							$ 149,018
Increase in debt principal amount							$ 3,000,000
Debt instrument description							the per share purchase price of the shares of our Common Stock sold in the Qualified Offering, and to change the references in the Revolving Note from “the six (6) month anniversary of October 28, 2016” to “July 25, 2017.”
Investor [Member] | Revolving Note [Member] | Maximum [Member]
Issuance of warrants to purchase of common stock shares												291,667
Warrant exercise price per share												$ 12
Advance pursuant to revolving note												$ 250,000
Investor [Member] | Revolving Note [Member] | Maximum [Member] | 15 Day Period [Member]
Advance pursuant to revolving note												250,000
Investor [Member] | Revolving Note [Member] | Maximum [Member] | 30 Day Period [Member]
Advance pursuant to revolving note												$ 500,000
Investor [Member] | Non-Convertible Loan [Member]
Amortized of debt discount																									68,687
Unamortized debt discount																								$ 12,420	$ 12,420
Original issue of discount percentage																								35.00%	35.00%
Convertible debt																								$ 0	$ 0
Number of shares issued								2,500
Investor [Member] | Non-Convertible Loan [Member] | 60 Days [Member]
Number of shares issued								8,333
Holder [Member]
Percentage of outstanding principal amount of debenture					5.00%
Equity ownership, percentage					5.00%
Gross proceeds of purchase consideration					$ 7,000,000
Private Investor [Member] | Non-Convertible Loan [Member]
Percentage of annual interest rates						20.00%
Debt fee amount						$ 32,000
Proceeds from loan						630,000
Unamortized debt discount																								$ 0	$ 0
Debt instrument interest amount						63,000
Due to related parties						31,500
Private Investor [Member] | Non-Convertible Loan [Member] | September 2016 Loan [Member]
Proceeds from loan						$ 589,189
Subscription Agreement [Member] | Individuals [Member] | July 23, 2015 and March 31, 2016 [Member]
Percentage of warrants to purchase shares of common stock																								50.00%	50.00%
Purchase warrants price amount																									$ 6,329,549
Debt principal amount																								$ 6,962,504	$ 6,962,504
Percentage of debt original issue discount on purchase price																									10.00%
Percentage of annual interest rates																								10.00%	10.00%
Debt conversion price per share																								$ 8.40	$ 8.40
Convertible debentures term																									2 years
Debt conversion amount																									$ 483,054
Gain on extinguishment of debt																									$ 218,452
Percentage of outstanding principal amount of debenture																									120.00%
Issuance of warrants to purchase of common stock shares																								376,759	376,759
Warrant exercise price per share																								$ 12	$ 12
Warrants expiration period																									5 years
Merchant Agreement [Member]
Amortized of debt discount																									$ 312,870	$ 40,802
Unamortized debt discount																								$ 48,194	48,194
Merchant Agreement [Member] | Non-Convertible Loan [Member] | Two Accredited Investor [Member]
Debt principal amount											$ 220,000
Gain on extinguishment of debt											33,000
Amortized of debt discount																									63,616
Unamortized debt discount											$ 43,616
Number of restricted stock issued during period											5,667
Debt fee percentage											10.00%
Original issue of discount percentage											10.00%
Merchant Agreement [Member] | Lender [Member] | Other Notes [Member]
Other note outstanding balance																								0	0
Merchant Agreement [Member] | Lender [Member] | Other Notes One [Member]
Other note outstanding balance																								0	0
Received in exchange for rights to all customer receipts																					$ 100,000
Payment of other notes																					129,900
Collected rate business day																					927
Debt fee amount																					$ 2,000
Proceeds from loan																							$ 125,000
Pay off prior loan amount																								48,420	48,420
Lender paid															$ 70,000
Merchant Agreement [Member] | Lender [Member] | Other Notes Two [Member]
Other note outstanding balance																								0	0
Merchant Agreement [Member] | Lender [Member] | Promissory Note [Member]
Debt principal amount																													$ 200,000
Debt conversion into common stock shares														3,335
Debt conversion amount														$ 41,200
Issuance of warrants to purchase of common stock shares																													3,333
Warrant exercise price per share																													$ 16.50
Amortized of debt discount														6,000
Fair value of warrant														27,349
Other note outstanding balance																								$ 0	$ 0
Repayment of debt														$ 206,000
Loan paid back date														Aug. 25, 2016
Merchant Agreement [Member] | Lender [Member] | Non-convertible Installment Loan [Member]
Proceeds from loan				$ 75,000
Loan fees paid				18,750
Payment of debt				93,750
Loans payable				$ 16,750

Convertible Debt and Other De50

Convertible Debt and Other Debt - Schedule of Convertible Debts and Outstanding Balances (Details) - USD ($)		12 Months Ended
		Dec. 31, 2017	Sep. 12, 2017	Jul. 22, 2015
Loan Amount		$ 4,093,500		$ 2,180,000
Outstanding Balance		$ 0
Interest Rate			10.00%
Conversion Price(Convertible at Inception Date)		$ 7.50
Deferred Finance Fees		$ 40,980
Convertible Notes [Member]
Loan Amount		8,973,049
Outstanding Balance		8,088,049
Original Issue Discount		749,696
Deferred Finance Fees		1,219,108
Discount related to Fair value of conversion feature and warrants		$ 6,124,178
Convertible Notes [Member] | Convertible Debt [Member]
Inception Date		Jul. 22, 2015
Term	[1]	30 months
Loan Amount		$ 2,180,000
Outstanding Balance		2,180,000
Original Issue Discount	[2]	$ 218,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 388,532
Discount related to Fair value of conversion feature and warrants		$ 2,163,074
Convertible Notes [Member] | Convertible Debt Two [Member]
Inception Date		Sep. 25, 2015
Term	[1]	30 months
Loan Amount		$ 1,100,000
Outstanding Balance		1,100,000
Original Issue Discount	[2]	$ 110,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 185,956
Discount related to Fair value of conversion feature and warrants		$ 1,022,052
Convertible Notes [Member] | Convertible Debt Three [Member]
Inception Date		Oct. 2, 2015
Term	[1]	30 months
Loan Amount		$ 150,000
Outstanding Balance		150,000
Original Issue Discount	[2]	$ 15,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 26,345
Discount related to Fair value of conversion feature and warrants		$ 140,832
Convertible Notes [Member] | Convertible Debt Four [Member]
Inception Date		Oct. 6, 2015
Term	[1]	30 months
Loan Amount		$ 30,000
Outstanding Balance		30,000
Original Issue Discount	[2]	$ 3,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 5,168
Discount related to Fair value of conversion feature and warrants		$ 26,721
Convertible Notes [Member] | Convertible Debt Five [Member]
Inception Date		Oct. 14, 2015
Term	[1]	30 months
Loan Amount		$ 50,000
Outstanding Balance		50,000
Original Issue Discount	[2]	$ 5,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 8,954
Discount related to Fair value of conversion feature and warrants		$ 49,377
Convertible Notes [Member] | Convertible Debt Six [Member]
Inception Date		Nov. 2, 2015
Term	[1]	30 months
Loan Amount		$ 250,000
Outstanding Balance		250,000
Original Issue Discount	[2]	$ 25,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 43,079
Discount related to Fair value of conversion feature and warrants		$ 222,723
Convertible Notes [Member] | Convertible Debt Seven [Member]
Inception Date		Nov. 10, 2015
Term	[1]	30 months
Loan Amount		$ 50,000
Outstanding Balance		50,000
Original Issue Discount	[2]	$ 5,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 8,790
Discount related to Fair value of conversion feature and warrants		$ 46,984
Convertible Notes [Member] | Convertible Debt Eight [Member]
Inception Date		Nov. 12, 2015
Term	[1]	30 months
Loan Amount		$ 215,000
Outstanding Balance		215,000
Original Issue Discount	[2]	$ 21,500
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 38,518
Discount related to Fair value of conversion feature and warrants		$ 212,399
Convertible Notes [Member] | Convertible Debt Nine [Member]
Inception Date		Nov. 20, 2015
Term	[1]	30 months
Loan Amount		$ 200,000
Outstanding Balance		200,000
Original Issue Discount	[2]	$ 20,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 37,185
Discount related to Fair value of conversion feature and warrants		$ 200,000
Convertible Notes [Member] | Convertible Debt Ten [Member]
Inception Date		Dec. 4, 2015
Term	[1]	30 months
Loan Amount		$ 170,000
Outstanding Balance		170,000
Original Issue Discount	[2]	$ 17,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 37,352
Discount related to Fair value of conversion feature and warrants		$ 170,000
Convertible Notes [Member] | Convertible Debt Eleven [Member]
Inception Date		Dec. 11, 2015
Term	[1]	30 months
Loan Amount		$ 360,000
Outstanding Balance		360,000
Original Issue Discount	[2]	$ 36,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 75,449
Discount related to Fair value of conversion feature and warrants		$ 360,000
Convertible Notes [Member] | Convertible Debt Twelve [Member]
Inception Date		Dec. 18, 2015
Term	[1]	30 months
Loan Amount		$ 55,000
Outstanding Balance		55,000
Original Issue Discount	[2]	$ 5,500
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 11,714
Discount related to Fair value of conversion feature and warrants		$ 55,000
Convertible Notes [Member] | Convertible Debt Thirteen [Member]
Inception Date		Dec. 31, 2015
Term	[1]	30 months
Loan Amount		$ 100,000
Outstanding Balance		100,000
Original Issue Discount	[2]	$ 10,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 20,634
Discount related to Fair value of conversion feature and warrants		$ 100,000
Convertible Notes [Member] | Convertible Debt Fourteen [Member]
Inception Date		Jan. 11, 2016
Term	[1]	30 months
Loan Amount		$ 100,000
Outstanding Balance		100,000
Original Issue Discount	[2]	$ 10,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 24,966
Discount related to Fair value of conversion feature and warrants		$ 80,034
Convertible Notes [Member] | Convertible Debt Fifteen [Member]
Inception Date		Jan. 20, 2016
Term	[1]	30 months
Loan Amount		$ 50,000
Outstanding Balance		50,000
Original Issue Discount	[2]	$ 5,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 9,812
Discount related to Fair value of conversion feature and warrants		$ 40,188
Convertible Notes [Member] | Convertible Debt Sixteen [Member]
Inception Date		Jan. 29, 2016
Term	[1]	30 months
Loan Amount		$ 300,000
Outstanding Balance		300,000
Original Issue Discount	[2]	$ 30,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 60,887
Discount related to Fair value of conversion feature and warrants		$ 239,113
Convertible Notes [Member] | Convertible Debt Seventeen [Member]
Inception Date		Feb. 26, 2016
Term	[1]	30 months
Loan Amount		$ 200,000
Outstanding Balance		200,000
Original Issue Discount	[2]	$ 20,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 43,952
Discount related to Fair value of conversion feature and warrants		$ 156,048
Convertible Notes [Member] | Convertible Debt Eighteen [Member]
Inception Date		Mar. 10, 2016
Term	[1]	30 months
Loan Amount		$ 125,000
Outstanding Balance		125,000
Original Issue Discount	[2]	$ 12,500
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 18,260
Discount related to Fair value of conversion feature and warrants		$ 106,740
Convertible Notes [Member] | Convertible Debt Nineteen [Member]
Inception Date		Mar. 18, 2016
Term	[1]	30 months
Loan Amount		$ 360,000
Outstanding Balance		360,000
Original Issue Discount	[2]	$ 36,000
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 94,992
Discount related to Fair value of conversion feature and warrants		$ 265,008
Convertible Notes [Member] | Convertible Debt Twenty [Member]
Inception Date		Mar. 24, 2016
Term	[1]	30 months
Loan Amount		$ 106,667
Outstanding Balance		106,667
Original Issue Discount	[2]	$ 10,667
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 15,427
Discount related to Fair value of conversion feature and warrants		$ 91,240
Convertible Notes [Member] | Convertible Debt Twenty One [Member]
Inception Date		Mar. 31, 2016
Term	[1]	30 months
Loan Amount		$ 177,882
Outstanding Balance		177,882
Original Issue Discount	[2]	$ 17,788
Interest Rate	[3]	10.00%
Conversion Price(Convertible at Inception Date)		$ 8.40
Deferred Finance Fees		$ 2,436
Discount related to Fair value of conversion feature and warrants		$ 175,446
Convertible Notes [Member] | Convertible Debt Twenty Two [Member]
Inception Date		Jun. 15, 2016
Term		6 months
Loan Amount		$ 40,000
Outstanding Balance
Original Issue Discount
Interest Rate		12.00%
Conversion Price(Convertible at Inception Date)		$ 13.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 3,680
Convertible Notes [Member] | Convertible Debt Twenty Three [Member]
Inception Date		Jun. 17, 2016
Term		6 months
Loan Amount		$ 40,000
Outstanding Balance
Original Issue Discount
Interest Rate		12.00%
Conversion Price(Convertible at Inception Date)		$ 13.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 3,899
Convertible Notes [Member] | Convertible Debt Twenty Four [Member]
Inception Date		Jun. 22, 2016
Term		6 months
Loan Amount		$ 35,000
Outstanding Balance
Original Issue Discount
Interest Rate		12.00%
Conversion Price(Convertible at Inception Date)		$ 13.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 3,373
Convertible Notes [Member] | Convertible Debt Twenty Five [Member]
Inception Date		Jul. 6, 2016
Term		6 months
Loan Amount		$ 85,000
Outstanding Balance
Original Issue Discount
Interest Rate		12.00%
Conversion Price(Convertible at Inception Date)		$ 13.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 15,048
Convertible Notes [Member] | Convertible Debt Twenty Six [Member]
Inception Date		Jul. 29, 2016
Term		6 months
Loan Amount		$ 100,000
Outstanding Balance
Original Issue Discount
Interest Rate		12.00%
Conversion Price(Convertible at Inception Date)		$ 13.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 25,518
Convertible Notes [Member] | Convertible Debt Twenty Seven [Member]
Inception Date		Sep. 15, 2016
Term		8 months
Loan Amount		$ 500,000
Outstanding Balance
Original Issue Discount		$ 85,541
Interest Rate		9.00%
Conversion Price(Convertible at Inception Date)		$ 13.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 65,972
Convertible Notes [Member] | Convertible Debt Twenty Eight [Member]
Inception Date		Oct. 11, 2017
Term		12 months
Loan Amount		$ 85,000
Outstanding Balance
Original Issue Discount
Interest Rate		5.00%
Conversion Price(Convertible at Inception Date)
Deferred Finance Fees		$ 4,250
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Twenty Nine [Member]
Inception Date	[4]	Oct. 20, 2017
Term	[4]	12 months
Loan Amount	[4]	$ 150,000
Outstanding Balance	[4]	150,000
Original Issue Discount	[4]
Interest Rate	[4]	5.00%
Conversion Price(Convertible at Inception Date)	[4]	$ 7.50
Deferred Finance Fees	[4]	$ 7,500
Discount related to Fair value of conversion feature and warrants	[4]
Convertible Notes [Member] | Convertible Debt Thirty [Member]
Inception Date		Oct. 25, 2017
Term		6 months
Loan Amount		$ 103,000
Outstanding Balance		103,000
Original Issue Discount
Interest Rate		12.00%
Conversion Price(Convertible at Inception Date)
Deferred Finance Fees		$ 3,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Thirty One [Member]
Inception Date		Oct. 27, 2017
Term		12 months
Loan Amount		$ 170,000
Outstanding Balance		170,000
Original Issue Discount
Interest Rate		5.00%
Conversion Price(Convertible at Inception Date)
Deferred Finance Fees		$ 4,250
Discount related to Fair value of conversion feature and warrants		$ 10,000
Convertible Notes [Member] | Convertible Debt Thirty Two [Member]
Inception Date		Nov. 13, 2017
Term		9 months
Loan Amount		$ 380,000
Outstanding Balance		380,000
Original Issue Discount		$ 15,200
Interest Rate		8.00%
Conversion Price(Convertible at Inception Date)		$ 7.50
Deferred Finance Fees		$ 15,200
Discount related to Fair value of conversion feature and warrants		$ 46,274
Convertible Notes [Member] | Convertible Debt Thirty Three [Member]
Inception Date		Nov. 22, 2017
Term		12 months
Loan Amount		$ 100,000
Outstanding Balance		100,000
Original Issue Discount		$ 10,000
Interest Rate		5.00%
Conversion Price(Convertible at Inception Date)
Deferred Finance Fees		$ 2,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Thirty Four [Member]
Inception Date		Nov. 28, 2017
Term		10 months
Loan Amount		$ 103,000
Outstanding Balance		103,000
Original Issue Discount		$ 3,000
Interest Rate		12.00%
Conversion Price(Convertible at Inception Date)
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Thirty Five [Member]
Inception Date		Nov. 29, 2017
Term		6 months
Loan Amount		$ 150,000
Outstanding Balance		150,000
Original Issue Discount
Interest Rate		15.00%
Conversion Price(Convertible at Inception Date)		$ 7.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants		$ 15,200
Convertible Notes [Member] | Convertible Debt Thirty Six [Member]
Inception Date		Nov. 30, 2017
Term		3 months
Loan Amount		$ 50,000
Outstanding Balance		50,000
Original Issue Discount
Interest Rate		8.00%
Conversion Price(Convertible at Inception Date)		$ 7.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Thirty Seven [Member]
Inception Date		Dec. 5, 2017
Term		3 months
Loan Amount		$ 52,500
Outstanding Balance		52,500
Original Issue Discount
Interest Rate		10.00%
Conversion Price(Convertible at Inception Date)		$ 7.50
Deferred Finance Fees		$ 2,500
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Thirty Eight [Member]
Inception Date		Dec. 6, 2017
Term		4 months
Loan Amount		$ 100,000
Outstanding Balance		100,000
Original Issue Discount
Interest Rate		10.00%
Conversion Price(Convertible at Inception Date)		$ 7.50
Deferred Finance Fees
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Thirty Nine [Member]
Inception Date		Dec. 11, 2017
Term		6 months
Loan Amount		$ 130,000
Outstanding Balance		130,000
Original Issue Discount		$ 1,500
Interest Rate		5.00%
Conversion Price(Convertible at Inception Date)
Deferred Finance Fees		$ 6,500
Discount related to Fair value of conversion feature and warrants		$ 6,460
Convertible Notes [Member] | Convertible Debt Forty [Member]
Inception Date		Dec. 19, 2017
Term		6 months
Loan Amount		$ 110,000
Outstanding Balance		110,000
Original Issue Discount		$ 1,500
Interest Rate		5.00%
Conversion Price(Convertible at Inception Date)
Deferred Finance Fees		$ 5,500
Discount related to Fair value of conversion feature and warrants		$ 5,775
Convertible Notes [Member] | Convertible Debt Forty One [Member]
Inception Date		Dec. 28, 2017
Term		6 months
Loan Amount		$ 55,000
Outstanding Balance		55,000
Original Issue Discount
Interest Rate		15.00%
Conversion Price(Convertible at Inception Date)		$ 7.50
Deferred Finance Fees		$ 5,000
Discount related to Fair value of conversion feature and warrants
Convertible Notes [Member] | Convertible Debt Forty Two [Member]
Inception Date		Dec. 29, 2017
Term		12 months
Loan Amount		$ 105,000
Outstanding Balance		105,000
Original Issue Discount
Interest Rate		5.00%
Conversion Price(Convertible at Inception Date)
Deferred Finance Fees		$ 5,000
Discount related to Fair value of conversion feature and warrants
[1]	The loan term was extended by 180 days and further extended on January 15, 2018 by 60 days to repay in common stock. The July 22, 2015 Debentures of $2,180,000 is currently past due as of March 19, 2018.
[2]	The original issue discount is reflected in the first year.
[3]	The annual interest starts accruing in the second year.
[4]	On October 20, 2017, Company issued to EMA Financial, LLC a 5% one year convertible note in the amount of $150,000, less $7,500 from OID and fees. The note is convertible at $7.50 per share, provided however, if the Company fails to comply with Section 1.9 of the note then the conversion price shall be 65% of the lowest sale price for the Common Stock on the Principal Market during the twenty (20) consecutive Trading Days immediately preceding the Conversion Date or the closing bid price, whichever is lower.

Convertible Debt and Other De51

Convertible Debt and Other Debt - Schedule of Convertible Debts and Outstanding Balances (Details) (Parenthetical) - USD ($)	Jul. 22, 2015	Dec. 31, 2017	Oct. 20, 2017	Sep. 12, 2017
Debt maturity description	The loan term was extended by 180 days and further extended on January 15, 2018 by 60 days to repay in common stock.
Debt principal amount	$ 2,180,000	$ 4,093,500
Debt maturity date	Mar. 19, 2018
Percentage of annual interest rates				10.00%
Debt conversion price per share		$ 7.50
One Year Convertible Loan [Member] | EMA Financial, LLC [Member]
Percentage of annual interest rates			5.00%
Debt conversion price per share			$ 7.50
Percentage of conversion price			65.00%

Convertible Debt and Other De52

Convertible Debt and Other Debt - Summary of Changes in Convertible Debt, Net of Unamortized Discounts (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Jul. 22, 2015
Debt Disclosure [Abstract]
Balance at January 1,	$ 5,273,937
Adjustment due to ASU 2017-11	923,468
Issuance of convertible debt, face value	4,093,500		$ 2,180,000
Deferred financing cost	(267,650)
Debt discount related to one-time interest charge	(225,000)
Debt discount from incentive shares to increase the Revolving Note aggregate principal limit	(150,000)
Debt discount from shares and warrants issued with the notes	(750,705)
Payments	(925,541)	$ (107,000)
Accretion of interest and amortization of debt discount to interest expense through September 30,	3,815,767
Balance at December 31,	11,787,776	$ 5,273,937
Less: current portion	11,787,776
Convertible debt, long-term portion

Convertible Debt and Other De53

Convertible Debt and Other Debt - Schedule of Merchant Agreements s (Details) - USD ($)		12 Months Ended
		Dec. 31, 2017	Sep. 12, 2017
Purchase Price		$ 1,775,750
Purchased Amount		2,330,538
Outstanding Balance		386,307
Interest Rate			10.00%
Deferred Finance Fees		$ 40,980
Merchant Agreements One [Member]
Inception Date	[1]	Jan. 6, 2016
Purchase Price	[1]	$ 250,000
Purchased Amount	[1]	322,500
Outstanding Balance	[1]
Daily Payment	[1]	$ 1,280
Interest Rate	[1]	14.00%
Deferred Finance Fees	[1]	$ 2,500
Merchant Agreements Two [Member]
Inception Date		Feb. 8, 2016
Purchase Price	[1]	$ 100,000
Purchased Amount	[1]	129,900
Outstanding Balance	[1]
Daily Payment	[1]	$ 927
Interest Rate	[1]	15.00%
Deferred Finance Fees	[1]	$ 2,000
Merchant Agreements Three [Member]
Inception Date		Aug. 16, 2016
Purchase Price		$ 70,000
Purchased Amount		90,930
Outstanding Balance
Daily Payment		$ 650
Interest Rate		15.00%
Deferred Finance Fees		$ 1,590
Merchant Agreements Four [Member]
Inception Date		Aug. 26, 2016
Purchase Price		$ 125,000
Purchased Amount		166,250
Outstanding Balance
Daily Payment		$ 1,386
Interest Rate		6.00%
Deferred Finance Fees		$ 2,535
Merchant Agreements Five [Member]
Inception Date		Feb. 6, 2017
Purchase Price		$ 125,000
Purchased Amount		161,250
Outstanding Balance
Daily Payment		$ 1,344
Interest Rate		15.00%
Deferred Finance Fees		$ 1,250
Merchant Agreements Six [Member]
Inception Date		Mar. 2, 2017
Purchase Price		$ 75,750
Purchased Amount		97,718
Outstanding Balance
Daily Payment		$ 776
Interest Rate		7.00%
Deferred Finance Fees		$ 750
Merchant Agreements Seven [Member]
Inception Date		Jun. 6, 2017
Purchase Price		$ 250,000
Purchased Amount		330,000
Outstanding Balance
Daily Payment		$ 1,833
Interest Rate		5.00%
Deferred Finance Fees		$ 6,250
Merchant Agreements Eight [Member]
Inception Date		Jun. 21, 2017
Purchase Price		$ 150,000
Purchased Amount		190,500
Outstanding Balance
Daily Payment		$ 1,361
Interest Rate		15.00%
Deferred Finance Fees		$ 1,498
Merchant Agreements Nine [Member]
Inception Date		Jul. 17, 2017
Purchase Price		$ 125,000
Purchased Amount		160,000
Outstanding Balance
Daily Payment		$ 1,250
Interest Rate		7.00%
Deferred Finance Fees		$ 1,250
Merchant Agreements Ten [Member]
Inception Date		Sep. 29, 2017
Purchase Price		$ 75,000
Purchased Amount		102,000
Outstanding Balance		(1,200)
Daily Payment		$ 1,200
Interest Rate		15.00%
Deferred Finance Fees		$ 1,500
Merchant Agreements Eleven [Member]
Inception Date		Oct. 25, 2017
Purchase Price		$ 110,000
Purchased Amount		153,890
Outstanding Balance		71,233
Daily Payment		$ 1,539
Interest Rate		15.00%
Deferred Finance Fees		$ 8,800
Merchant Agreements Twelve [Member]
Inception Date		Dec. 7, 2017
Purchase Price		$ 160,000
Purchased Amount		212,800
Outstanding Balance		157,088
Daily Payment		$ 1,252
Interest Rate		25.00%
Deferred Finance Fees		$ 5,799
Merchant Agreements Thirteen [Member]
Inception Date		Dec. 12, 2017
Purchase Price		$ 160,000
Purchased Amount		212,800
Outstanding Balance		159,186
Daily Payment		$ 1,252
Interest Rate		15.00%
Deferred Finance Fees		$ 5,258
[1]	The Company recognized a gain in fiscal year 2016 on the settlement of the previous loan of $5,044 which was credited to interest expense.

Convertible Debt and Other De54

Convertible Debt and Other Debt - Schedule of Merchant Agreements s (Details) (Parenthetical)	Dec. 31, 2017USD ($)
Merchant Agreements Two [Member]
Advances from officers	$ 5,044

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Dec. 12, 2017	Dec. 11, 2017	Sep. 20, 2017	Sep. 12, 2017	Jun. 09, 2017	May 10, 2017	May 02, 2017	Apr. 19, 2017	Mar. 21, 2017	Mar. 14, 2017	Dec. 12, 2016	Jul. 22, 2015	Dec. 23, 2014	Nov. 12, 2014	Jun. 30, 2014	Feb. 28, 2014	Feb. 02, 2014	Jan. 29, 2014	Dec. 12, 2013	Mar. 28, 2013	Feb. 06, 2013	Jan. 04, 2013	Nov. 15, 2012	Jul. 06, 2012	Nov. 11, 2011	Dec. 31, 2017	Jan. 31, 2017	Nov. 30, 2016	Dec. 31, 2013	Apr. 30, 2012	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2017	Aug. 18, 2017	Oct. 28, 2016	Nov. 29, 2015	Sep. 22, 2014	Apr. 04, 2014	Jan. 31, 2014	Dec. 21, 2013	Dec. 28, 2012
Convertible preferred stock, authorized																										1,000,000					1,000,000	1,000,000
Convertible preferred stock, par value																										$ 0.01					$ 0.01	$ 0.01
Convertible preferred stock, shares issued																										1,000,000					1,000,000	1,000,000
Proceeds from warrants issued																																$ 186,802
Number of shares issued to investor, shares				3,333
Shares issued during period, value																																	$ 610,000
Convertible debt balance																										$ 0					$ 0	0
Fair value of warrant																																$ 2,847,624
Common stock, shares outstanding under the plan																										1,147,234					1,147,234	1,147,234	1,057,632	1,159,964
Number of common stock value issued for consulting and investor services																																$ 46,992	$ 332,696
Number of shares issued to debenture holders																																61,307
Gain on extinguishment of debt																																$ 185,452	5,044
Number of restricted stock value	$ 600,000
Percentage of annual interest rates				10.00%
Original issue of discount percentage				35.00%
Number of warrant to purchase common stock																										$ 9,878,513					$ 9,878,513	9,878,513	6,325,102
Debt principal amount												$ 2,180,000														4,093,500					4,093,500	4,093,500
Unamortized debt discount				$ 25,000																						401,856					401,856	$ 401,856	$ 2,235,839
Amortization of interest expenses				13,000
Proceeds from loan				$ 225,000
Debt instrument, maturity date												Mar. 19, 2018
Number of restricted common stock shares issued	150,000		4,000
Privately-held Investment Firm [Member]
Number of shares issued to investor, shares								8,333
Percentage of annual interest rates								10.00%
Original issue of discount percentage								10.00%
Number of shares issued at closing								833
Investor [Member] | Every Sixty Days [Member]
Number of shares issued to investor, shares								2,500
Debenture Holders [Member]
Number of shares issued to debenture holders																																61,307
Accrued interest																										$ 483,054					$ 483,054	$ 483,054
Gain on extinguishment of debt																																$ 218,452
Noteholders [Member]
Number of shares issued to investor, shares		25,000
Shares issued during period, value		$ 9,500
Debt principal amount		$ 170,000
Debt instrument, maturity date		Feb. 15, 2018
Minimum [Member]
Percentage of annual interest rates																										5.00%					5.00%	5.00%
Maximum [Member]
Percentage of annual interest rates																										12.00%					12.00%	12.00%
Series G Warrants [Member]
Warrant exercise price																										$ 15					$ 15	$ 15
Common Stock [Member]
Number of shares issued to investor, shares																																	50,834
Shares issued during period, value																																	$ 508
Number of common stock shares issued for services																										2,134						5,667	25,167
Number of common stock value issued for consulting and investor services																																$ 57	$ 252
Number of shares issued to debenture holders																															9,700		14,028
Unamortized debt discount																										$ 37,435					$ 37,435	$ 37,435
Series D Registered Direct Offering [Member]
Warrant exercise price						$ 8.40
Proceeds from warrants issued						$ 140,214
Number of shares issued to investor, shares						19,889
Number of warrants to purchase common stock, shares						39,778
Fair value of warrant						$ 186,802
Value of shares invested in private placements						$ 8,950
2005 Equity Incentive [Member]
Common stock reserved for stock option plan																										1,800,000					1,800,000	1,800,000
Common stock, shares outstanding under the plan																										35,274					35,274	35,274
2013 Equity Incentive Plan [Member]
Common stock reserved for stock option plan																			3,000,000
Common stock, shares outstanding under the plan																			82,481
Common stock, shares available for future grant																			2,917,519
2015 Equity Incentive Plan [Member]
Common stock reserved for stock option plan																																						5,000,000
Common stock, shares outstanding under the plan																																						129,937
Common stock, shares available for future grant																																						4,870,063
Unrecognized compensation cost																																$ 392,590
Compensation cost reorganization period																																1 year 7 months 28 days
Restricted Common Stock [Member]
Number of restricted stock value																																$ 16,000
Restricted Common Stock [Member] | Administrative Expenses [Member]
Number of restricted stock value																																$ 15,000
Series D Warrant [Member]
Warrant exercise price																										$ 24.30			$ 7.50	$ 12	$ 24.30	$ 24.30
Change in number of warrants																													20,958	17,681
Number of warrants issued during period																													55,887	34,930
Series J Warrant [Member]
Warrant exercise price																										12					12	12
Stock issuance price per share																										$ 24					$ 24	$ 24
Series J Warrant [Member] | Minimum [Member]
Change in number of warrants																																5,000,000
Warrants expiration date																																May 20, 2016
Series K Warrant [Member]
Proceeds from direct offering																	$ 5,000,000
Warrant exercise price														$ 9.38	$ 11.25	$ 12.75		$ 9.38																								$ 9.38
Warrant Derivative Liability [Member]
Proceeds from direct offering																																$ 171,733
Warrant exercise price																																	$ 12	$ 12
Warrant expiring term																																5 years	5 years	5 years
Aggregate warrant to lenders to purchase common stock shares																																	83,902	292,262
Aggregate warrant to placement agent to purchase common stock shares																																	13,750	56,310
Non-Convertible Loan [Member]
Number of shares issued to investor, shares								8,333
Percentage of annual interest rates								10.00%	10.00%	10.00%
Original issue of discount percentage								10.00%	10.00%	10.00%																									35.00%
Proceeds from loan								$ 250,000		$ 250,000
Non-Convertible Loan [Member] | Privately-held Investment Firm [Member]
Proceeds from non convertible debt								$ 250,000
Non-Convertible Loan [Member] | Investor [Member]
Convertible debt balance																										$ 0					$ 0	$ 0
Original issue of discount percentage																										35.00%					35.00%	35.00%
Unamortized debt discount																										$ 12,420					$ 12,420	$ 12,420
Non-Convertible Loan [Member] | Investor [Member]
Convertible debt balance																										$ 170,000					$ 170,000	$ 170,000
Number of shares issued to debenture holders																																9,500
Original issue of discount percentage																										35.00%					35.00%	35.00%
Unamortized debt discount																										$ 7,238					$ 7,238	$ 7,238
Number of restricted common stock shares issued									5,667	8,333
Revolving Note [Member]
Warrant exercise price							$ 12
Number of warrants to purchase common stock, shares							16,667
Fair value of warrant																																$ 291,667
Number of warrant to purchase common stock							$ 3,000,000
Debt principal amount																																				$ 3,500,000
Revolving Note [Member] | Investor [Member]
Warrant exercise price							$ 12																														$ 12
Number of shares issued to investor, shares							16,667
Shares issued during period, value							$ 149,018
Number of warrants to purchase common stock, shares																																					20,834
Revolving Note [Member] | Maximum [Member] | Investor [Member]
Warrant exercise price																																					$ 12
Number of warrants to purchase common stock, shares																																					291,667
Series A Junior Participating Preferred Stock [Member]
Number of stock designated																										20,000					20,000	20,000
Series A Convertible Preferred Stock [Member]
Number of stock designated																										313,960					313,960	313,960
Series B Convertible Preferred Stock [Member]
Number of stock designated																										279,256					279,256	279,256
Series C Convertible Preferred Stock [Member]
Number of stock designated																										88,098					88,098	88,098
Series D Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																										850					850	850	850
Convertible preferred stock, par value																									$ 0.01	$ 0.01					$ 0.01	$ 0.01	$ .01
Convertible preferred stock, shares issued																										300					300	300	300
Number of stock designated																										850					850	850
Aggregate number of units sold																									843
Purchase price per units sold																									$ 1,000
Proceeds from direct offering																									$ 843,000
Warrant exercise price																									$ 24.30
Issuance of warrants to purchase of common stock shares																									21
Conversion of stock into shares																									84
Additional paid in capital and accumulated deficit																																$ 530,140
Adjustment to additional paid in capital related to the beneficial conversion feature																																530,140
Amount to be paid at any uncertain situation value per share (subject to accrued but unpaid dividends)																										$ 1,000					$ 1,000	$ 1,000
Change in exercise price of warrants																										$ 19.50					$ 19.50	$ 19.50
Convertible preferred stock, conversion percentage																																300.00%
Average daily trading volume																																50,000
Ownership, percentage																										50.00%					50.00%	50.00%
Preferred stock value issued																										$ 3					$ 3	$ 3	$ 3
Series D Convertible Preferred Stock [Member] | Series D Warrant [Member]
Proceeds from warrants issued																																283,725
Proceeds from convertible preferred stock																																$ 559,275
Series E Convertible Preferred Stock [Member]
Number of stock designated																										500					500	500
Series G Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																										240,000					240,000	240,000	240,000
Convertible preferred stock, par value																							$ 0.01	$ 0.01		$ 0.01					$ 0.01	$ 0.01	$ 0.01
Convertible preferred stock, shares issued																										80,570					80,570	80,570	86,570
Number of stock designated																										240,000					240,000	240,000
Aggregate number of units sold																							4,844	4,844
Purchase price per units sold																							$ 150	$ 150
Proceeds from direct offering																							$ 726,600	$ 726,600
Warrant exercise price																										$ 15					$ 15	$ 15
Issuance of warrants to purchase of common stock shares																																5
Conversion of stock into shares					2,000
Convertible preferred stock, conversion percentage																																12.00%
Value of shares invested in private placements																																$ 726,600
Warrant expiring term																								3 years
Cumulative dividend rate percentage																																4.00%
Percentage of shares purchased for investment																																6.00%
Preferred stock value issued																										$ 806					$ 806	$ 806	$ 866
Stock issuance price per share																										$ 22.50					$ 22.50	$ 22.50
Conversion of stock					6,000
Series G Convertible Preferred Stock [Member] | Minimum [Member]
Proceeds from direct offering																																$ 2,500,000
Average daily trading volume																																334
Value of shares invested in private placements																																$ 250,000
Preferred stock value issued																										$ 100,000					$ 100,000	100,000
Series G Convertible Preferred Stock [Member] | Maximum [Member]
Preferred stock value issued																										$ 250,000					$ 250,000	$ 250,000
Series H Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																										10,000					10,000	10,000	10,000										10,000
Convertible preferred stock, par value																						$ 0.01				$ 0.01					$ 0.01	$ 0.01	$ 0.01
Convertible preferred stock, shares issued																										10,000					10,000	10,000	10,000
Number of stock designated																										10,000					10,000	10,000
Purchase price per units sold																						$ 24.08
Issuance of warrants to purchase of common stock shares																						4
Preferred stock value issued																										$ 100					$ 100	$ 100	$ 100										$ 100,000
Number of common shares exchanged																						33,334
Series H2 Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																										21					21	21	21
Convertible preferred stock, par value													$ 0.01													$ 0.01					$ 0.01	$ 0.01	$ 0.01
Convertible preferred stock, shares issued													21													21					21	21	21
Number of stock designated																										21					21	21
Purchase price per units sold													$ 7.50
Issuance of warrants to purchase of common stock shares													3,334
Preferred stock value issued
Number of common shares exchanged													70,000
Series J Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																										6,250					6,250	6,250	6,250
Convertible preferred stock, par value																				$ 0.01	$ 0.01					$ 0.01					$ 0.01	$ 0.01	$ 0.01
Convertible preferred stock, shares issued																										3,458					3,458	3,458	3,521
Number of stock designated																										6,250					6,250	6,250
Aggregate number of units sold																				5,087.5	5,087.5
Purchase price per units sold																				$ 400	$ 400
Proceeds from direct offering																				$ 2,034,700	$ 2,034,700
Warrant exercise price																				$ 12	$ 12
Conversion of stock into shares					2,100
Value of shares invested in private placements																					$ 250,000
Preferred stock value issued																					$ 250,000					$ 35					$ 35	$ 35	$ 35
Stock issuance price per share																										$ 24					$ 24	$ 24
Conversion of stock					63															34	34
Series J Convertible Preferred Stock [Member] | Minimum [Member]
Average daily trading volume																																1,667
Value of shares invested in private placements																																$ 2,500,000
Series K Convertible Preferred Stock [Member]
Convertible preferred stock, authorized																										15,000					15,000	15,000	15,000
Convertible preferred stock, par value														$ 0.01	$ 0.01	$ 0.01		$ 0.01	$ 0.10							$ 0.01					$ 0.01	$ 0.01	$ 0.01
Convertible preferred stock, shares issued														34	34	34		34								6,880					6,880	6,880	6,816						2,134
Number of stock designated																										15,000					15,000	15,000
Aggregate number of units sold														1,052	734	1,854		4,875	4,000
Purchase price per units sold														$ 250	$ 300	$ 340		$ 250	$ 250
Proceeds from direct offering														$ 263,000	$ 220,000	$ 630,360		$ 1,218,750	$ 1,000,000													$ 100,000
Warrant exercise price														$ 9.38	$ 11.25	$ 12.75										$ 9.38					$ 9.38	$ 9.38
Issuance of warrants to purchase of common stock shares														17	17	17		17														34
Proceeds from warrants issued																																$ 271,422
Proceeds from convertible preferred stock																																685,245
Adjustment to additional paid in capital related to the beneficial conversion feature																																$ 1,495,415
Convertible preferred stock, conversion percentage																																4.00%
Average daily trading volume																																1,667
Number of warrants issued during period																																17
Value of shares invested in private placements														$ 3,332,110																		$ 1,000,000
Preferred stock value issued																										$ 68					$ 68	$ 68	$ 68
Stock issuance price per share																										$ 24					$ 24	$ 24
Warrants expiration date														Nov. 12, 2017	Jun. 30, 2017	Feb. 28, 2017		Jan. 29, 2017
Cash received in private placement														$ 2,511,404																		$ 572,044
Fee incurred with private placement																																$ 43,334
Percentage of stock acquired																																6.00%
Conversion of outstanding indebtedness and accrued board of directors' fees														820,706												$ 427,956					$ 427,956	$ 427,956
Increase in subscription amount																$ 3,500,000		$ 718,750
Number of shares returned																										64					64	64
Number of common stock shares issued for services																																2,134
Number of common stock value issued for consulting and investor services																																$ 15,992
Series K Convertible Preferred Stock [Member] | Tranche Two [Member]
Proceeds from direct offering																		$ 1,500,000
Increase in subscription amount																																									$ 1,218,750
Series K Convertible Preferred Stock [Member] | Tranche Third [Member]
Proceeds from direct offering																1,500,000
Increase in subscription amount																$ 630,360
Series K Convertible Preferred Stock [Member] | Fourth Tranche [Member]
Proceeds from direct offering															$ 1,500,000
Increase in subscription amount															$ 220,000
Series K Convertible Preferred Stock [Member] | Fifth Tranche [Member]
Proceeds from direct offering														1,500,000
Increase in subscription amount														$ 263,000
Series K Convertible Preferred Stock [Member] | Initial Tranche [Member]
Increase in subscription amount																			$ 1,000,000
Series K Convertible Preferred Stock [Member] | Minimum [Member]
Proceeds from direct offering											$ 2,500,000
Increase in subscription amount																																								$ 4,500,000
Series K Convertible Preferred Stock [Member] | Maximum [Member]
Increase in subscription amount																																								$ 1,000,000
Restricted Common Stock [Member] | Investor [Member]
Number of common stock shares issued for services																											3,334	11,000
Number of common stock value issued for consulting and investor services																											$ 15,558	$ 84,735

Stockholders' (Deficit) - Sched

Stockholders' (Deficit) - Schedule of Assumption Used (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Nov. 10, 2011
Fair value per warrant		$ 16.20
Series K Warrants December 12, 2013 [Member]
Contractual life (in months)	36 months
Expected volatility	136.10%
Risk-free interest rate	0.39%
Exercise price	$ 9.38
Fair value per warrant	$ 6
Series K Warrants January 29, 2014 [Member]
Contractual life (in months)	36 months
Expected volatility	152.40%
Risk-free interest rate	0.39%
Exercise price	$ 9.38
Fair value per warrant	$ 9
Series K Warrants February 28, 2014 [Member]
Contractual life (in months)	36 months
Expected volatility	152.70%
Risk-free interest rate	0.39%
Exercise price	$ 12.75
Fair value per warrant	$ 11.10
Series K Warrants June 30, 2014 [Member]
Contractual life (in months)	36 months
Expected volatility	153.90%
Risk-free interest rate	90.00%
Exercise price	$ 11.25
Fair value per warrant	$ 8.70
Series K Warrants November 12, 2014 [Member]
Contractual life (in months)	36 months
Expected volatility	153.90%
Risk-free interest rate	90.00%
Exercise price	$ 9.38
Fair value per warrant	$ 6.90

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Concerning Options and Warrants Outstanding and Exercisable (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Shares, Beginning balance	1,057,632	1,159,964
Shares, Granted	332,859	272,652
Shares, Exercised	(19,889)	(2,334)
Shares, Expired	(211,421)	(368,785)
Shares, Forfeited	(11,946)	(3,866)
Shares, Ending balance	1,147,234	1,057,632
Exercisable, Beginning balance	991,032	1,055,483
Exercisable, Ending balance	1,073,850	991,032
Stock Option [Member]
Shares, Beginning balance	175,642	185,708
Shares, Granted	87,198
Shares, Exercised
Shares, Expired	(3,202)	(6,200)
Shares, Forfeited	(11,946)	(3,866)
Shares, Ending balance	247,692	175,642
Weighted average price per share, Beginning balance	$ 12.60	$ 13.20
Weighted average price per share, Granted	8.40
Weighted average price per share, Exercised
Weighted average price per share, Expired	30	30
Weighted average price per share, Forfeited	9.82	15.30
Weighted average price per share, Ending balance	$ 10.95	$ 12.60
Warrants [Member]
Shares, Beginning balance	881,989	974,256
Shares, Granted	245,661	272,652
Shares, Exercised	(19,889)	(2,334)
Shares, Expired	(208,219)	(362,585)
Shares, Forfeited
Shares, Ending balance	899,542	881,989
Weighted average price per share, Beginning balance	$ 12	$ 13.20
Weighted average price per share, Granted	11.14	12.60
Weighted average price per share, Exercised	7.50	9.30
Weighted average price per share, Expired	11.46	16.50
Weighted average price per share, Forfeited
Weighted average price per share, Ending balance	$ 12.03	$ 12

Stockholders' Deficit - Sched58

Stockholders' Deficit - Schedule of Share-based Compensation Stock Option Plans by Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Exercise price range, lower range limit	$ 7.50
Exercise price range, upper range limit	$ 30
Options outstanding, number of options | shares	247,692
Options outstanding, weighted average remaining contractual life (years)	7 years 6 months
Options outstanding, weighted average exercise price	$ 10.95
Options exercisable, number of options | shares	174,308
Options exercisable, weighted average remaining contractual life (years)	7 years
Options exercisable, weighted average exercise price	$ 11.59
Exercise Price 1 [Member]
Exercise price range, lower range limit	7.50
Exercise price range, upper range limit	$ 11.99
Options outstanding, number of options | shares	133,580
Options outstanding, weighted average remaining contractual life (years)	8 years 3 months 19 days
Options outstanding, weighted average exercise price	$ 8.63
Options exercisable, number of options | shares	80,997
Options exercisable, weighted average remaining contractual life (years)	7 years 8 months 12 days
Options exercisable, weighted average exercise price	$ 8.78
Exercise Price 2 [Member]
Exercise price range, lower range limit	12
Exercise price range, upper range limit	$ 14.99
Options outstanding, number of options | shares	88,705
Options outstanding, weighted average remaining contractual life (years)	7 years 8 months 12 days
Options outstanding, weighted average exercise price	$ 12
Options exercisable, number of options | shares	67,904
Options exercisable, weighted average remaining contractual life (years)	7 years 7 months 6 days
Options exercisable, weighted average exercise price	$ 12
Exercise Price 3 [Member]
Exercise price range, lower range limit	15
Exercise price range, upper range limit	$ 17.99
Options outstanding, number of options | shares	7,547
Options outstanding, weighted average remaining contractual life (years)	4 years 7 months 6 days
Options outstanding, weighted average exercise price	$ 15
Options exercisable, number of options | shares	7,547
Options exercisable, weighted average remaining contractual life (years)	4 years 7 months 6 days
Options exercisable, weighted average exercise price	$ 15
Exercise Price 4 [Member]
Exercise price range, lower range limit	18
Exercise price range, upper range limit	$ 20.99
Options outstanding, number of options | shares	12,854
Options outstanding, weighted average remaining contractual life (years)	2 years 1 month 6 days
Options outstanding, weighted average exercise price	$ 18
Options exercisable, number of options | shares	12,854
Options exercisable, weighted average remaining contractual life (years)	2 years 1 month 6 days
Options exercisable, weighted average exercise price	$ 18
Exercise Price 5 [Member]
Exercise price range, lower range limit	21
Exercise price range, upper range limit	$ 30
Options outstanding, number of options | shares	5,006
Options outstanding, weighted average remaining contractual life (years)	2 years 8 months 12 days
Options outstanding, weighted average exercise price	$ 30
Options exercisable, number of options | shares	5,006
Options exercisable, weighted average remaining contractual life (years)	2 years 8 months 12 days
Options exercisable, weighted average exercise price	$ 30

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 31, 2018	Mar. 12, 2018	Feb. 22, 2018	Feb. 12, 2018	Jan. 19, 2018	Jan. 16, 2018	Jan. 03, 2018	Dec. 12, 2017	Sep. 20, 2017	Mar. 31, 2018	Jan. 31, 2018	Mar. 31, 2018	Feb. 15, 2018	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2017	Sep. 12, 2017	Aug. 18, 2017	Apr. 19, 2017	Mar. 21, 2017	Mar. 14, 2017	Jul. 22, 2015
Number of common stock shares issued in lieu of cash														$ 46,992	$ 332,696
Debt conversion price per share														$ 7.50
Number of restricted common stock agreed to issue								$ 600,000
Debt instrument, fee amount														$ 40,980
Debt interest rate																	10.00%
Payments for outstanding balance of previous loan														925,541	$ 107,000
Debt principal amount														$ 4,093,500								$ 2,180,000
Number of restricted common stock issued, shares								150,000	4,000
Original issue of discount percentage																	35.00%
Non-Convertible Loan [Member]
Debt interest rate																			10.00%	10.00%	10.00%
Original issue of discount percentage																35.00%			10.00%	10.00%	10.00%
Revolving Note [Member]
Debt principal amount																		$ 3,500,000
Subsequent Event [Member] | Merchant Agreement [Member] | Lender [Member]
Received in exchange for rights to all customer receipts			$ 110,000
Payment of other notes			147,400
Collected rate per business day			$ 921
Subsequent Event [Member] | Revolving Note [Member]
Proceeds from convertible debt										$ 500,000	$ 500,000
Debt principal amount		$ 4,000,000
Subsequent Event [Member] | Debenture Holders [Member]
Number of common stock shares issued in lieu of cash, shares												12,494
Number of common stock shares issued in lieu of cash												$ 52,371
Subsequent Event [Member] | Board of Directors [Member]
Number of common stock shares issued in lieu of cash, shares												1,092
Subsequent Event [Member] | Accredited Investors [Member]
Proceeds from convertible debt	$ 150,000
Debt, term	6 months
Original issue discount, percentage	10.00%									10.00%		10.00%
Subsequent Event [Member] | Accredited Investor [Member] | Non-Convertible Loan [Member]
Proceeds from convertible debt													$ 170,000
Debt, term				8 months
Number of restricted common stock issued, shares				3,500
Number of restricted common stock shares yet to be issued	3,500
Subsequent Event [Member] | Accredited Investor [Member] | Convertible Loan [Member]
Proceeds from convertible debt		$ 253,000		$ 100,000	$ 150,000	$ 131,250	$ 95,000
Debt, term		6 months		6 months	6 months	1 year
Debt conversion, original debt, amount		$ 53,000
Debt conversion price per share		$ 7.50		$ 7.50	$ 7.50
Number of restricted common stock agreed to issue		$ 6,750			$ 4,000
Debt interest rate				10.00%	10.00%	4.00%	5.00%
Payments for outstanding balance of previous loan				$ 50,000
Number of restricted common stock issued, shares				5,000
Original issue of discount percentage					10.00%
Debt converted into common stock, percentage						4.00%	40.00%
Subsequent Event [Member] | Privately-held Investment Firm [Member] | Convertible Loan [Member]
Proceeds from convertible debt		85,000
Debt instrument, fee amount		$ 5,400